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1. Introduction 
1.1. History of MDMA 
3, 4 Methylenedioxymethamphetamine (MDMA) was first synthesized and patented by the 
German pharmaceutical company Merck in Darmstadt around 1912, merely as a precursor in a new 
chemical pathway which was patented in order to avoid an infringement of existing patent for the 
synthesis of the clotting agent hydrastinine (Freudenmann RW et al., 2006). The first formal animal 
study on MDMA done by Hardman HF et al. in 1953-54 (US army studies) consisted of a number 
of LD50 determinations on five laboratory animal species, including the mouse. MDMA was first 
used by humans in the late 1960s, where it showed its properties of inducing feelings of well-being 
and increased communication (Watson L and Beck J. 1991). There was a phase of therapeutic 
enthusiasm for this drug as adjunct to psychotherapy due to its ability to enhance feelings of 
openness and trust and cause a sense of deep harmony in the self and in relationships with other 
persons (Grinspoon L and Bakalar JB. 1986). The drug was introduced in clinical psychotherapeutic 
practice on the West Coast of the United States in the beginning of 1976 (Shulgin A. 1990). There 
were reports of cases of toxicity and deaths from exposure to large doses of MDMA in United 
States and Europe (Dowling GP et al., 1987) and several researchers reported long-term neurotoxic 
effects of MDMA in laboratory animals (Ricaurte G et al., 1985; Schmidt CJ et al., 1986; Stone 
DM et al., 1986). Until the mid 1980s, drug use was restricted predominantly to people taking the 
drug when alone in a small party (Peroutka SJ et al., 1988). Whereas since the late 1980s, MDMA 
has been used as a street drug (street names include “Ecstasy”, “XTC”, “Adam”, “Essence”, 
“Clarity”). The Food and Drug Administration placed the compound on Schedule I control 
substance on July1, 1985. MDMA is now used extensively at dance clubs at parties called “raves”, 
and it is this new use that has probably given rise to a substantial increase in the number of reports 
of toxic reactions and deaths (Schwartz RH and Miller NS. 1997). Despite increasing reports of the 
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potential neurotoxicity, as well as deaths, related to MDMA use, the popularity of this drug has 
increased tremendously over the years making it at high concern for mental health professionals. 
Table 1: Milestones from the history of MDMA/Ecstasy (Freudenmann RW et al., 2006) 
 
1.2. Epidemiology and abuse studies 
The national institute on drug abuse in 2008 estimated 2.1 million Americans aged 12 and 
older had abused MDMA at least once in their life. Over 32 million people or almost 10% of the 
adult population in the European Union and Norway used the drug in 2008, according to the annual 
report of the European Monitoring Center for Drugs and Drug Addiction (EMCDDA). In that 
around 2 million drug users in Europe preferred amphetamine while ecstasy was used by 2.5 million 
people. Approximately 12 million have tried amphetamine and 10 million have tried ecstasy at least 
once in their lives. The use of ecstasy is overtaking the other amphetamines and getting the second 
place, after cannabis, in both general population and school surveys (EMCDDA 2008). It has been 
estimated that the percentage of ecstasy consumers in Italy is stable and approximately represent 
22% of total drug abusers (http://aloearborescens.tripod.com/fumo.htm). 
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1.3. Statistics showing emergency room visits due to drug abuse in USA 
From the data available in literature very clear picture of consumption of MDMA can be 
seen. First graph shows that total rate of Emergency Room (ER) visits among 'ecstasy' users is 
approximately 1 in 600 users per year. The second graph shows the increase in ER visits from 1994 
to 2002 with MDMA abuse. The number of ER visits rapidly increased from 1994-2001, declining 
in 2002 (apparently due to reduced rates of use, Fig. 2). Most of this increase was simply due to the 
greatly increased number of people using 'ecstasy' (http://www.thedea.org/statistics.html). 
 
Figure 1: Emergency room (ER) visits due to drug abuse in 2001 (USA). 
 
Figure 2: Graph showing emergency room (ER) visits due to MDMA drug abuse from 1995 to 2002 
(USA). 
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Table 2: Deaths caused by MDMA abuse from 1994 to 2001 (USA). 
 Year: 1994 1995 1996 1997 1998 1999 2000 2001* 
Reported 
Deaths: 1 6 8 3 9 42 63 76 
 
In the Table 2 it is shown the number of deaths due to MDMA abuse. The increase in death 
reports (Table 2) does, however, better match the increases in Emergency Room visits (Figure 2). 
The basis of reporting MDMA deaths is not exactly associated with MDMA abuse as ecstasy tablets 
usually contains varying amounts of MDMA and may contain some other substances such as 
caffeine, amphetamines and 3,4 methylenedioxyamphetamine (MDA) which could be harmful to 
humans. Administration of MDMA has reinforcing effects as showed by studies on MDMA – 
induced place preference (Bilsky EJ et al., 1990) and intravenous self administration in rodents (De 
La Garza R et al., 2007). Moreover, the reinforcing effects of MDMA have been investigated in 
rhesus monkeys, although its reinforcing efficacy appears to be less than that of cocaine or 
methamphetamine (Lile JA et al., 2005). 
 
1.4. Chemical Structure and Mechanisms of Action of MDMA 
As its chemical name implies, MDMA bears the intrinsic structure of amphetamine (AMPH) 
with an N-methyl group and a methylenedioxy-ring substitution on the third and fourth carbon of 
the phenyl ring (Figure 3). It is thought that this variation in structure is responsible for 
dichotomous effects on brain neurochemistry exerted by these two substances. More specifically, 
AMPH and its derivative, methamphetamine (METH) has potent and long lasting effects on the 
dopamine (DA) neuromodulatory system while, in the long-term, MDMA affects mainly the 
serotonergic system. Additionally, MDMA more subtly affects the dopamine, norepinephrine (NE), 
gamma-aminobutyric acid (GABA), glutamate, and other systems as well (Green AR et al., 2003).  
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Figure 3: Chemical structure of amphetamine, methamphetamine, and MDMA (Green AR et al., 
2003).  
 
Acutely, MDMA causes a rapid efflux of serotonin (5-hydroxytryptamine; 5-HT), NE, and 
DA from respective monoaminergic terminals. In terms of serotonergic release, this effect is 
mediated by the drug’s interaction with both the plasmalemmal serotonin transporter (SERT) as 
well as with the intracellular vesicular monoamine transporter 2 (VMAT-2), both proteins being 
involved in the selective transport of 5-HT across phospholipid bilayers. More specifically, MDMA 
is a substrate for both SERT and VMAT-2, allowing it to enter the terminal and subsequently 
vesicles bearing 5-HT, respectively (Rudnick G and Wall SC. 1992). Once inside the vesicles, the 
slightly alkaline nature of MDMA causes dissipation of the proton gradient between the vesicle and 
the cytosol necessary for proper functioning of VMAT-2, and in this respect, it inhibits VMAT-2-
mediated influx and proper storage of 5-HT in the terminal (Sulzer D and Rayport S. 1990). 
Coupled with its ability to cause functional reversal of both VMAT-2 and SERT, MDMA allows 5-
HT to passively efflux from terminal vesicles and subsequently from the neuron itself, ultimately 
leading to a global increase in extracellular 5-HT throughout brain regions bearing raphe afferents 
(Rudnick G and Wall SC. 1992). This effect is further potentiated by MDMA-induced inhibition of 
5-HT reuptake, as consequence of competition for SERT-binding by both 5- HT and MDMA. 
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1.5. Pharmacology and Toxicity of MDMA 
1.5.1. In Humans 
MDMA the main component of ecstasy tablet has various harmful health effects in humans. 
The neurotoxic dose of MDMA in non-human primates approaches the dose of MDMA typically 
taken by recreational MDMA users and it is found to be 1.5 to 1.7 mg/kg in humans and 5 mg/kg in 
monkeys (www.drugtext.org/library/articles/ricaurte.htm). The acute effects after taking MDMA 
are hyponatraemia (headaque, confusion or altered mental state, seizures), hyperthermia is one of 
the causes for death due to MDMA. Approximately 15 young persons die every year from acute 
MDMA toxic effects. The reason may be that MDMA is usually taken recreationally in dance clubs 
or in rave parties in hot, crowded rooms (both conditions leads to larger elevation of MDMA-
induced body temperature in animals) therefore clinically such conditions could increase the 
possibility of subsequent cerebral neurotoxic effect. Several case reports have been reported fatal 
hyperthermia after ingestion of ecstasy. The patient collapsed with the seizures they tended to have 
a very fast heart rate and very low blood pressure and body temperature as high as 43°C (Henry JA 
et al., 1992; Green et al., 2004). Chronic studies by Mc Cann et al., 1994 found selective reductions 
in cerebrospinal fluid of 5 – hydroxyindoleacetic acid (5-HIAA) in MDMA users compared to 
control that never used it. Positron emission tomography (PET) studies showed evidence of 
decreased 5HT transporter sites correlated with the degree of MDMA exposure. It has also been 
found that, there is altered neuroendocrine function in MDMA users which can be correlated to 
alterations of hypothalamic 5HT function, suggestive of MDMA-induced 5-HT neurotoxicity. 
Neuropsychiatric testing methods found that MDMA users, compared to controls, had deficits in 
verbal and visual memory (Morgan MJ. 1999). Pharmacological depletion of brain 5-HT typically 
leads to dramatic decrease in non-rapid eye movement (NERM) sleep with less dramatic decreases 
in rapid eye movement (REM) sleep associated decreased total sleep time compared to controls (Mc 
Cann UD et al., 2000). 
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1.5.2. In Monkeys 
Monkeys administered with MDMA showed a marked reduction in the number and density 
of 5-HT containing nerve fibers in the cortical, but also in the sub cortical regions. The MDMA 
treated animal has much fewer 5-HT containing axons. A series of studies were recently completed 
where monkeys were examined seven years after MDMA treatment. These animals still showed 
evidence of serotonin axon loss. This suggests that in monkeys the toxic effect of MDMA may be 
permanent (www.drugtext.org/library/articles/ricaurte.htm). The available preclinical data from 
monkeys tend to suggest that one or two episodes of repeated, high-dose exposure to MDMA are 
not sufficient to produce obvious disruptions of cognitive or behavioral function, despite producing 
large and lasting depletions of 5-HT in the neocortex (Frederick DL et al. 1998; Taffe MA et al. 
2001; Winsauer PJ et al., 2002). MDMA produces an acute hyperthermia in unrestrained rhesus 
monkeys, much as it does with rats, mice, pigs, rabbits and humans (Taffe MA et al., 2006). 
 
1.5.3. In Rats 
MDMA administration in rats is known to release 5-HT in striatum and medial prefrontal 
cortex dose dependently which may lead to marked decrease in 5-HT concentration (Green AR et 
al., 2003). Treatement with MDMA also decreases 5-HT transporter level. A significant reduction 
in tryptophan hydroxylase (TPH), a rate limiting enzyme required for 5-HT synthesis is observed in 
the hippocampus, striatum and frontal cortex of hyperthermic animal’s resulting in decreased 
cerebral tissue concentrations of 5-HT and 5-HIAA after MDMA administration. However 
tryptophan hydroxylase (TPH) activity was unaltered in hypothermic animals after administration 
of MDMA (Stone DM et al., 1987, Che S et al., 1995). In addition MDMA also inhibits the 
catabolic enzyme monoamine oxidase (MAO) having potency 10 times greater at MAO–A than 
MAO-B. MDMA also rapidly increases dopamine release in striatum and causes a sustained 
depletion of DOPAC and HVA. The release of dopamine by MDMA occurs through entering in 
dopamine nerve terminals and is modulated by 5-HT2A/2C receptors. MDMA administration to rats 
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has generally been reported to produce a marked hyperthermic response of approximately +1-2°C 
when kept in 22°C ambient temperature, while hypothermic response at 17°C indicating a high 
sensitivity to small changes in ambient temperature. MDMA also induces increase in glial fibrillary 
acidic protein (GFAP) expression in the hippocampus that paralleled 5-HT damage and was 
prevented in the same way by α- lipoic acid administration (Green AR et al., 2003). 
 
1.5.4. In Mice 
In contrast to the MDMA pharmacological effects in rats, MDMA administration in mice 
causes a small decrease in 5-HT and 5-HIAA in cortex and hippocampus with little effect on 
striatum. Whereas it causes a rapid release of dopamine in striatum and reduces striatal content of 
both dopamine and its metabolites HVA and DOPAC. It is observed that administration of 
dopamine reuptake inhibitor GBR 12909 enhanced the MDMA induced increase in extracellular 
dopamine concentration indicating that MDMA may enter nerve terminal by diffusion and not via 
dopamine reuptake site (Camarero J et al., 2002). It has also been shown that proinflammatory 
molecules such as inducible nitric oxide are increased one day after administration of MDMA and 
that their inhibition provides protection against MDMA-induced loss of DA in striatum (Granado N 
et al., 2008). A study by Thomas DM et al., 2004 showed that MDMA induces significant 
microgliosis in striatum and SNc. MDMA induced hyperthermia though much more variable has 
been seen in mice. Also in mice MDMA at a dose of 10mg/kg induced hypothermia while 30mg/kg 
induced hyperthermia followed by hypothermia in Swiss Webster mice. The locomotor activity 
seen in mice is found to be mediated by 5-HT1B receptor (Green AR et al., 2003).  
 
1.6. Mechanism Involved in MDMA Toxicity 
Though lot of studies have been carried out to understand mechanism involved in MDMA 
induced neurotoxicity still there is no much success. It is very well known that free radicals are 
involved in MDMA induced neurotoxicity but it is not yet known the source for free radicals which 
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may be from release of excess of dopamine, from mitochondrial complex I inhibition, or from 
formation of toxic MDMA metabolites. 
 
1.6.1. Oxidative stress 
Several studies using animal models supported the involvement of oxidative stress in 
MDMA neurotoxicity. The role of oxidative stress is further supported by the findings that 
neurotoxic effects of MDMA can be attenuated by free radical scavengers and anti-oxidants. The 
reactive oxygen and nitrogen species involved in oxidative stress are suppose to be formed from 
release of excess of dopamine in cytosol or from formation of neurotoxic MDMA metabolites 
(Puerta E et al., 2010). MDMA induces rapid and powerful release of dopamine in mice which is 
metabolised by MAO-B and leads to formation of DA quinones as well as hydrogen peroxide. 
Attenuation of DA release by lesioning DA neurons or blocking DA transporter has been shown to 
protect against the long term toxicity of MDMA. In addition, oxidation of 5-HT, MDMA itself, and 
thioether metabolites of MDMA has also been implicated in MDMA neurotoxicity. MDMA has 
now been shown to increase hydroxyl radical formation in rats; consequently these highly reactive 
free radicals can lead to the generation of lipid peroxidation and oxidize proteins in the nerve 
terminals (Quinton MS et al., 2006). Camarero J et al., (2002) reported that administration of 
MDMA led to rise in the formation of 2, 3 dihydroxybenzoic acid (2, 3 DHBA) and 
malonyldialdehyde, a lipid peroxidation product, in mice striatum. In addition to reactive oxygen 
species, reactive nitrogen species now appear to play a major role in mediating MDMA-induced 
neurotoxicity. Neuronal nitric oxide synthase activation seems to be involved in MDMA 
neurotoxicity which generates NO. This generated NO and peroxide radical from DA metabolism 
combines together to form peroxinitrite (ONOO -) which promotes autooxidation of DA to DA 
quinone and also has been found to inhibit DAT (Chipana C et al. 2006). Similarly, Colado MI et al 
reported in 2001 that neuronal NOS inhibitors provided significant neuroprotection against MDMA 
– induced long term dopamine depletion in mice.  
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The development of various transgenic knockout mouse models has helped to elucidate 
various mechanisms underlying MDMA-mediated neurotoxicity. Homozygous and heterozygous 
copper/zinc superoxide dismutase (an antioxidant enzyme) transgenic mice were partially protected 
against MDMA-mediated DA damage. Moreover, MDMA causes a decrease in catalase and 
glutathione peroxidase, and an increase in lipid peroxidation in wild-type animals, effects that are 
not observed in the homozygous mice (Jayanthi S et al., 1999). 
 
1.6.2. Excitotoxicity  
Excitotoxicity includes succession of several events, excessive glutamate release, activation 
of glutamate receptors and increase in intracellular calcium levels which leads to generation of free 
radicals and nitric oxide (Bruno V. et al., 1993; Yamamato BK et al., 2010). In fact glutamate and 
other excitatory amino acids have been linked to several neurodegenerative disorders suggesting a 
possible role of glutamate in Methamphetamine and MDMA- induced terminal degeneration 
(Lipton SA et al., 1994; Quinton MS et al., 2006).  Battaglia G et al. (2002) showed that selective 
blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine- 
induced toxicity to DA terminals suggesting a role of glutamate in amphetamine toxicity while 
studies by Colado MI et al., (2001) showed that there is no involvement or release of glutamate and 
calcium with MDMA in mice.  
 
1.6.3. Mitochondrial Dysfunction 
In addition to the increased oxidative stress, more recent evidence suggests an important role 
of the mitochondrial electron transport chain (ETC) in mediating the toxic effects of substituted 
amphetamines. The first evidence of inhibition of ETC by MDMA was given by Burrows KB et al., 
(2000) where they observed significant inhibition of cytochrome oxidase activity in the substantia 
nigra, the nucleus accumbens, and the striatum. In line with this study Puerta E et al., (2010) 
recently reported that inhibition of complex I of the mitochondrial electron transport chain is one of 
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the earlier events that take place in MDMA-induced neurotoxicity in mice. Aconitase, a krebs cylcle 
enzyme sensitive enough to reflect in situ reactive oxygen species (ROS) generation in 
mitochondria was significantly decreased after MDMA treatment, supporting possible involvement 
of O2- in MDMA induced dopamine toxicity. MDMA toxicity may derive from peroxinitrite that is 
formed by the diffusion related reaction of O2- with NO. These findings are supported by the fact 
that mice genetically deficient in neuronal NOS and mice overexpressing human CuZn-SOD are 
less sensitive to MDMA toxicity compared with their wild- type counterparts. In turn lipoic acid 
prevents MDMA-induced 5-HT deficits in rats and dopamine deficits in mice striatum by inhibiting 
O2- production and peroxinitrite- meidiated DNA strand breakage. 
 
 
Figure 4: MDMA induced mitochondrial complex I inhibition and free radical formation (Puerta E 
et al., 2010) 
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1.6.4. Formation of toxic MDMA metabolites  
Recent study by Yuan J et al., 2010 reported that dopamine is not essential for the 
development of methamphetamine-induced neurotoxicity giving more stress on involvement of 
amphetamine metabolites in amphetamine toxicity. Several studies already reported that it’s not 
MDMA but the metabolite of MDMA that induces different neurotoxic effects. With regard to 
MDMA toxicity Escobedo I et al., (2005) showed that intrastriatal administration of MDMA at a 
dose much higher than the peripherally administered neurotoxic dose, does not induce 
neurotoxicity. So as to produce neurotoxic effects, MDMA has to get metabolised peripherally and 
then the metabolite of MDMA induces different neurotoxic effects. The parent compound MDMA 
is N-demethylated to form 3, 4 -methylenedioxyamphetamine (MDA) and O - demethylenated to 
form 3, 4 -dihydroxymethamphetamine (HHMA). HHMA is further O-methylated to 4-hydroxy-3-
methoxymethamphetamine (HMMA). In rats, N-demethylation to MDA is one of the main 
metabolic pathways, whereas in humans O-demethylenation to HHMA predominates. 3, 4 -
Dihydroxyamphetamine (HHA) and HHMA are the precursors of neurotoxic species (De La Torre 
et al., 2004). The N- demethylation product 3,4-methylenedioxyamphetamine (MDA) which 
undergoes oxidation by GSH to form 5-(GSyl)-α–MeDA and might be the main neurotoxic 
metabolite involved in rats. Studies by Miller RT et al., (1996) reported that intracerebroventricular 
(icv) administration of 5-(glutathion-S-yl)-R-MeDA (720 nmol) to male Sprague-Dawley rats 
produced behavioral changes similar to those reported after subcutaneous adminstration of MDA 
and also caused short-term alterations in the dopaminergic, serotonergic, and noradrenergic 
systems. Pretreatment of rats with acivicin an inhibitor of γ glutamyl transpeptidase (γ-GT) 
increases brain uptake of 5-GSyl-R-MeDA. Thus potentiates MDA and MDMA-mediated 
depletions in serotonin (5-HT) and 5-hydroxylindole acidic acid (5-HIAA) concentrations in brain 
regions enriched in 5-HT nerve terminal axons (striatum, cortex, hippocampus, and hypothalamus) 
(Bai F et al., 2001).  
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The ring hydroxylation of MDMA yields products such as 6-hydroxy- MDMA (6-OH-
MDMA) and 2,4,5-trihydroxymethamphetamine (THMA). The intracerebroventricular (i.c.v.) 
administration of 6-OH-MDMA does not produce a decrease in tryptophan hydroxylase activity 
(Elayan I et al., 1992; Zhao et al., 1992); however, the i.c.v. and intrastriatal administration of 
THMA produced 5-HT depletion and decreased tryptophan hydroxylase activity (Elayan I et al., 
1992; Johnson M et al., 1992; Zhao ZY et al., 1992). 
In mice, MDMA-induced neurotoxicity is mainly dopamine - mediated as MDMA causes 
the release of dopamine, which leads to the generation of reactive oxygen species as a result of 
dopamine oxidation. In other animal species, including humans, hepatic metabolism is a key factor 
involved in the production of MDMA toxicity to 5-HT-containing neurons (De La Torre et al., 
2004).  
 
Figure 5. Pathways of 3,4-methylenedioxymethamphetamine (MDMA) metabolism in rats and in 
humans. Isoenzymes of cytochrome P450 (CYP) involved in the N-demethylation and O-
demethylenation metabolic reactions in rats are highlighted in blue whereas those corresponding to 
enzymes in humans are shown in red (De La Torre R et al., 2004). 
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1.6.5. Hyperthermia  
One of the mechanisms implicated in MDMA neurotoxicity is a hyperthermic response 
induced by the repeated administration of a drug. In rats hyperthermia results primarily from 
dopamine release and is influenced by dose, ambient temperature and other housing conditions. 
Rats housed at an ambient temperature of 11°C, MDMA produced a dose-dependent hypothermic 
response while at an ambient temperature of 24°C a hyperthermic response occurred. MDMA 
interferes with heat loss mechanisms and consequently the higher the ambient temperature the more 
impaired the ability to lose heat to the environment. The metabolic rate was increased in the 
MDMA treated rats at an ambient temperature of both 20 and 30°C. Though MDMA causes major 
release of both 5-HT and dopamine, SCH23390 dopamine D1 receptor antagonist was found to be 
protective against MDMA induced hyperthermia. Cytokines such as interleukin 1β, interleukin-6 
and tumour necrosis factor-α increase body temperature acting by direct or indirect mechanisms on 
the brain. After MDMA administration to rats there is an acute increase in interleukin-1β 
concentration in the hypothalamus and cortex (Green RA et al., 2004). Whereas studies by Orio L 
et al., (2004) reported that interleukin -1β could be the consequence, rather than the cause of 
MDMA induced hyperthermia. In mice MDMA induced hyperthermia appears to be more variable 
than that seen in rats. Both the dose administered and strain of mouse appears to influence the size 
and direction of response detected. The mechanism by which MDMA induces hyperthermia in mice 
appears not to involve the acute dopaminergic effects (Green RA et al., 2003; 2004). Maintenance 
of animals at low ambient temperatures (10 °C) before and after treatment with MDMA prevents 
the hyperthermic response and either attenuates or eliminates the MDMA-induced neurotoxicity 
(Schmidt CJ et al., 1990; Broening HW et al., 1995). In contrast some agents such as fluoxetine, 
which provide protection against MDMA induced neurotoxicity, do not block the MDMA induced 
increase in temperature (Cadet JL et al., 2007). Taken together this evidence indicates that 
hyperthermia has an important modulatory role but is not an essential factor in the neurotoxicity 
induced by the drug.  
15 
 
1.6.6. Neuroinflammation 
Neuroinflammation is found to be one of the factors involved in MDMA induced 
neurotoxicity and minocycline an anti-inflammatory drug was found to have a neuroprotective 
effect against MDMA induced neurotoxicity (Zhang L et al., 2006). Inflammatory response in CNS 
has been associated with many chronic neurodegerative conditions including Alzheimer's disease, 
Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Whether 
neuroinflammation is a cause or a consequence of neurologic disease remains unclear. It is observed 
that infection, trauma, stroke, toxins and other stimuli may cause an acute neuroinflammatory 
response which leads to activation of the resident immune cells (microglia) resulting in a phagocytic 
phenotype and the release of inflammatory mediators such as cytokines and chemokines. This acute 
neuroinflammatory response may trigger oxidative and nitrosative stress which is short lived and 
unlikely to be detrimental to long-term neuronal survival. In contrast chronic neuroinflammation 
includes not only longstanding activation of microglia and subsequent sustained release of 
inflammatory mediators, but also results in increased oxidative and nitrosative stress. Rather than 
serving a protective role as does acute neuroinflammation, chronic neuroinflammation is most often 
detrimental and damaging to nervous tissue. Thus, whether neuroinflammation has beneficial or 
harmful outcomes in the brain may depend critically on the duration of the inflammatory response. 
Neuropathological and neuroradiological studies indicate that neuroinflammatory responses may 
begin prior to significant loss of neuronal populations in the progression of neurodegerative 
diseases (Frank-Cannon TC et al., 2009). 
 
1.7. Glial cells 
Neuroglial cells of the central nervous system (CNS) include the astrocytes, 
oligodendrocytes, and microglia, whereas glia in the peripheral nervous system (PNS) is composed 
of Schwann cells. It is now well established that glial cells represent intimate partners to neurons 
throughout their lifespan. For example, during neurogenesis and early development, glial cells 
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provide a scaffold for the proper migration of neurons and growth cones, a process mediated via the 
synthesis and secretion of a variety of growth factors and extracellular matrix components. Glial 
cells also provide guidance cues for neuronal proliferation and electrical differentiation of neurons. 
In the adult, glial cells maintain neuronal homeostasis, synaptic plasticity, and repair (Achner M et 
al., 1999). 
 
Figure 6: Balance of Inflammation. (Abbreviations: Helper T-cell Type I (TH1), Tumor necrosis 
factor (TNF), Interleukin-1 (IL-1), Matrix Metalloprotease (MMP), Helper T-cell Type II (TH2), 
Transforming Growth Factor (TGF), Brain Derived Neurotrophic Factor (BDNF), Nerve Growth 
Factor (NGF), Neurotropic Factor 3 (NT3), and Glial-Derived Neurotrophic Factor (GDNF)). 
 
In the healthy brain glia often respond to stress and insults by transiently upregulating 
inflammatory processes. These processes are kept in check by other endogenous anti-inflammatory 
and neuroprotective responses that return the brain to homeostasis. In neurodegenerative disorders, 
however, pro-inflammatory processes predominate and contribute to the neuronal damage observed. 
Several examples of proinflammatory and neurodegenerative mediators are given (left column in fig 
5), as well as examples of anti-inflammatory and neuroprotective factors (right column in fig 5).  
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1.7.1. Microglial cells 
Microglia reside in the CNS, comprise approximately 12% of the brain (depending on brain 
region, health, or pathology), and serve as the brain’s immune defense. Analogous to the role of 
macrophages and lymphocytes in the periphery, one role of microglia is to act as the brain’s 
immune defense against disease and injury. Resting ramified, microglia cell bodies are spaced 
throughout the CNS to avoid cell body overlap, but have been shown to be present with variable 
density in different brain regions. The expression of certain receptors, such as CD200 and CX3CR1 
on the microglia cell surface, may interact with ligands that keep microglia in a resting state. When 
reacting to extracellular signals, such as the presence of pathogens, foreign material, and dead or 
dying cells, microglia may undergo a morphological change into an ameboid shape with short or 
nonexistent processes. This morphological change is also accompanied by changes in signaling and 
gene expression that can result in changes in surface receptor expression, the release of pro- or anti-
inflammatory factors, recruitment molecules, and ROS, among others. In the developing brain and 
in areas of remodeling, microglia are responsible for the phagocytosis of cellular debris resulting 
from apoptosis and normal cell death. Microglia have been implicated as the “brain’s electricians, in 
which the release of neurotrophic factors and anti-inflammatory cytokines from microglia has been 
shown to promote synaptic plasticity. In fact, the majority of microglial functions are beneficial and 
necessary for a healthy CNS, as activated microglia are critical for CNS wound healing. In addition, 
microglias have also been shown to release anti-inflammatory and trophic molecules to enhance the 
survival of surrounding neurons. 
In contrast microglia is a predominant source of proinflammatory factors [TNF-α (tumour 
necrosis factor α), PGE2 (prostaglandin E2) and IFN-γ (interferon γ),] and oxidative stress (●NO, 
H2O2, O2●- and ONOO-/ONOOH) which are toxic to neurons. Although microglia is necessary for 
normal function, microglia when activated by an extensive list of pro-inflammatory stimuli, such as 
lipopolysaccharide (LPS), pesticides (e.g., paraquat, lindane and rotenone), disease proteins, α 
synnuclein, and even neuron damage, can result in disastrous neurotoxic consequences. Microglia 
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also has been implicated to play both causative and exacerbating roles in neurodegerative diseases. 
Neurodegenerative diseases are characterized by chronic and progressive neuronal loss, and 
pathological levels of cytotoxic substances, such as extracellular debris, elevated levels of pro-
inflammatory factors, and production of reactive oxygen species, resulting in oxidative stress. These 
factors, in addition to the release of others that can activate and recruit microglia, support a role for 
microglia in diseases, such as Alzheimer’s disease, PD, multiple sclerosis, amyotrophic lateral 
sclerosis, and HIV-associated neurocognitive disorder. Pioneering work by Mc Geer et al., (1998) 
discovered increased staining of the MHC class II cell surface receptor HLA-DR in the substantia 
nigra (SN) of postmortem PD patient brains, indicating the presence of activated microglia, and first 
implicating that these cells may have an active pathological role in disease. It is hypothesized that 
microglial activation results in selective dopamine neurotoxicity due to the inherent susceptibility of 
the dopamine neuron to oxidative stress. Microglia is a robust source of oxidative stress in the brain, 
where extracellular ROS is predominantly generated from NADPH oxidase. NADPH oxidase is a 
multi-subunit enzyme complex in phagocytes such as microglia, which is activated during host 
defence to catalyse the production of superoxide from oxygen. A variety of stimuli, including 
bacteria, inflammatory peptides and multiple neurotoxins activate NADPH oxidase. In addition, this 
enzyme complex is associated with neurodegerative disorders and neuronal damage. (Lull ME et 
al., 2010, Block ML et al., 2007) 
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Figure 7: Release of proinflammatory factors from activated microglia and its effects on 
doapminergic neuron. 
 
1.7.2. Astroglia 
Astrocytes are one of the two primary types of macroglia. They comprise nearly 35% of the 
total CNS cell population and like microglia are found in all regions of the CNS. Histologically, 
astrocytes can be visualized by immunolabeling with antisera specific for glial fibrillary acidic 
protein (GFAP), S100b or the astrocyte specific glutamate transporters, GLT1 and GLAST (Carson 
MJ et al., 2006). In the healthy, uninjured CNS, astrocytes perform numerous functions absolutely 
essential for neuronal function. In case of injury, astrocytes can phagocytose injured cells after 
which they replace them and form a glial scar. They are slow to react to injury, but stay activated 
during the late recovery stage (Gehrmann J et al. 1995). Astrocytes produce several growth factors 
and regulate the induction and maintenance of neurite outgrowth, axonal guidance and synapse 
formation (Gee JR and Keller JN, 2005). Their most amazing function is probably their role in the 
tripartite synapse, which consist of the presynaptic neuron, the postsynaptic neuron and the 
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astrocyte itself. Astrocytes act as a physical link between the pre- and postsynaptic neurons on one 
side and blood capillaries on the other, which is important for maintaining the external environment 
for optimal functioning of the neurons. Astrocyte interactions with the cerebrovasculature 
endothelium play a key role in the induction and maintenance of the tight junction’s characteristic 
of the intact BBB and can influence BBB permeability when needed (Carson MJ et al., 2006). 
Astrocytes detect synaptic activity by binding of neurotransmitters to receptors on the astrocytic 
membrane. By secreting vasoactive substances, astrocytes can regulate the blood flow in reaction to 
varying levels of neuronal activity, since an active brain region requires more oxygen and energy 
(Parri R and Crunelli V 2003, Benarroch EE 2005). A large body of evidence indicates that 
astrocytes are involved in the control of glutamate homeostasis and susceptibility of the brain to 
excitotoxic injury. Glutamate transporters are expressed in many different types of brain cells, but 
astrocytes are primarily responsible for glutamate uptake. After uptake of glutamate into astrocytes, 
the enzyme glutamine synthetase converts glutamate into glutamine, which is then transported into 
neurons where it is converted back into glutamate (Boison D et al., 2010). Besides terminating the 
action of glutamate, astrocytes are also responsible for the clearance of γ-aminobutyric acid 
(GABA) and glycine, which both are inhibitory neurotransmitters. However, maintaining synapses 
and uptake of neurotransmitter and thereby terminating the presynaptic signals are not the only 
functions of the astrocyte in the tripartite synapse. Astrocytes have G-protein coupled receptors that 
bind neurotransmitters, ATP or adenosine. This enables them to monitor the activity of neurons 
directly (Fields and Stevens-Graham 2002). Activation of these G-protein coupled receptor results 
in an intracellular [Ca2+] rise in the astrocyte causing the release of chemical transmitters, including 
several neurotransmitters, ATP and D-serine (Fields RD and Stevens-Graham B 2002; Halassa MM 
et al. 2006). The secreted chemical transmitters are also called gliotransmitters and they give 
feedback to neurons, influencing neuronal excitability and synaptic strength. Different responses 
might be elicited by secreting different types of gliotransmitters, depending on the characteristics of 
the [Ca2+] response evoked. One of these gliotransmitters is ATP, which can bind the presynaptic 
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neuron thereby modulating synaptic transmission. ATP also binds receptors on neighbouring 
astrocytes, inducing inositol triphosphate (IP3) formation that subsequently triggers the release of 
Ca2+ stored in the endoplasmatic reticulum (ER). This way, astrocytes are capable of 
communicating with each other. Astrocytes can be a significant source of extracellular glutamate, 
which can be released by a variety of mechanisms. It has been demonstrated that Ca2+ elevations in 
astrocytes induce excitotoxic release of glutamate from these cells. It was shown that astrocyte-
derived glutamate targets synaptic N-methyl-D-aspartic acid (NMDA) receptors providing a 
rationale explanation for the astrocyte-based control of neurotoxicity (Boison D et al., 2010). 
 
Figure 8: Glutamate transporters in astrocytes are responsible for synaptic glutamate homeostasis 
(Liu YP et al., 2008). 
 
1.8. Adenosine receptors and their localisation in brain 
There are four types of membrane-bound adenosine receptors, named A1, A2A, A2B, and A3 
receptors. All four subtypes are members of the superfamily of G-protein-coupled-receptors 
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(GPCRs) with seven transmembrane domains that signal through a variety of transduction 
mechanisms. Out of the four adenosine receptors, the A1 receptor is the most abundant and 
widespread in the brain. The highest expression of A1 receptors has been found in the cortex, 
cerebellum, thalamus and hippocampus.  Moreover, the mRNA encoding A1 receptor is also present 
in basal ganglia structures including the striatum, globus pallidus, subthalamic nucleus. It is also 
known that in the striatum, A1 receptors are present on both dopaminergic nigrostriatal and 
glutamatergic corticostriatal terminals. Moreover, they are co-localized with dopamine D1 receptors 
on GABA/dynorphin output neurons which send their terminals to the substantia nigra pars 
reticulata. A1 receptors are also present in astrocytes, microglia and oligodendrocytes (Wardas J et 
al., 2002). A1 receptors are most abundant in the presynaptic active zone and post-synaptic density. 
In contrast to the widespread distribution of A1 receptors in the brain, A2A receptors are highly 
concentrated in the basal ganglia predominantly located in dendritic spines and post synaptic 
densities of cortical and thalamic glutamatergic projections and medium spiny GABAergic neurons, 
where their density is about 20 times greater than elsewhere in the brain. With regard to specific 
neuronal populations in the striatum, A2A receptors are present in striatopallidal enkephalin - 
expressing neurons. The same cells also express dopamine D2 receptors; hence both A2A and D2 
receptors are distributed on the same neuronal pathway. Apart from this A2A receptors are also 
located in astrocytes and microglia cells as well as in brain blood vessel, most likely in endothelial 
cells. Both in-situ hybridization, binding, immunological and functional studies have concluded that 
A2A receptors are located in limbic and neocortical regions in the brain. In conclusion A1 receptors 
are mostly located presynaptically and also have a post-synaptic localization. Whereas A2A 
receptors are present mainly presynaptically, the striatum is exception, where A2A receptors are 
located post-synaptically (Cunha RA et al., 2005). Due to low abundance in the brain, the role of 
A2B and A3 receptors has received considerably less attention. A2B is expressed in intermediate 
levels in blood vessels, eye, median eminence, mast cells and in low levels in the adrenal and 
pituitary glands. At the cellular level, it has been demonstrated their biochemical existence in 
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neurons and glial cells (Daly JW 1977; Fredholm BB et al., 2005). A3 is expressed at low levels in 
the rat or mouse brain, for example in cortex, amygdala, striatum, olfactory bulb, nucleus 
accumbens, hippocampus, hypothalamus, thalamus and cerebellum (Linden J et al., 1993; Salvatore 
CA et al., 1993; Dixon AK et al., 1996). At the cellular level it is expressed in neurons (Lopes LV 
et al., 2003), astrocytes (Wittendorp MC et al., 2004) and microglial cells (Moreau JL and Huber G, 
1999; Hammarberg C et al., 2003). 
 
Figure 9: Distribution of adenosine A1 and A2A receptors in the brain. Bigger fonts indicate high 
level of expression.  
 
1.9. Role of adenosine in the central nervous system 
At a cellular level, adenosine has a neuromodulatory role on nerve activity, by modulating 
the release of neurotransmitters, the post-synaptic responsiveness and the action of other receptor 
systems (Cunha RA, 2001). The A1 receptor inhibits synaptic transmission, acting both pre and 
post-synaptically in brain regions with a high concentration of these receptors, such as the 
hippocampus (Dunwiddie TV and Masino SA, 2001). A1 receptor stimulation inhibits the release of 
most classical neurotransmitters: glutamate, acetylcholine, norepinephrine, 5-hydroxytryptmanine, 
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dopamine and other transmitters (Dunwiddie TV and Haas HL, 1985; Schubert P et al., 1986; 
Proctor WR and Dunwiddie TV, 1987; Barrie AP and Nicholls DG, 1993; Ambrósio AF et al., 
1997). A2A receptor mediates facilitation of the release of neurotransmitters such as glutamate 
(Lopes LV et al., 2002), acetylcholine (Rebola N et al., 2002) and serotonin (Okada M et al., 2001), 
among others. In many regions this effect is only seen if A1 receptor is present (Lopes LV et al., 
2002), but A2A receptor can also facilitate the release of neurotransmitters independently of A1 
receptor, as typified by the control of the evoked release of GABA (Gubitz AK et al., 1996; Cunha 
RA and Ribeiro JA, 2000; Brooke RE et al., 2004). The final target of A2A receptor modulation in 
nerve terminals seems to be P-type calcium channels (Mogul DJ et al., 1993; Gubitz AK et al., 
1996). The overall neuromodulatory role of adenosine in the CNS is a balance between A1 and A2A 
receptor functions, because they are the two mainly expressed adenosine receptors in the brain 
(compared to A2B and A3) and they can be located at the same synapse (Rebola N et al., 2005b). In 
the hippocampus, the percentage of nerve terminals with A2A that are simultaneously endowed with 
A1 is 80% (Rebola et al., 2005a). The A2A receptor has a major role in controlling A1 receptor 
through intracellular transducing systems (Dixon AK et al., 1997; Lopes LV et al., 1999) or through 
receptor dimerization (Ciruela F et al., 2006). Adenosine can possess other functions such as 
controlling the rate of metabolism of neurons and astrocytes (Håberg A et al., 2000; Hammer J et 
al., 2001), axonal growth (Rivkees SA et al., 2001) or axonal guidance (Corset V et al., 2000; Stein 
E et al., 2001). Adenosine receptors can also control astrogliosis, the release of neuroactive 
substances (Hindley S et al., 1994; Ciccarelli R et al., 2001), inflammation (Ohta A and Sitkovsky 
M, 2001) and vascular resistance (Olsson RA and Pearson JD, 1990). 
 
1.10. Adenosine and neuroprotection 
Adenosine is released upon stressful situations (Fredholm BB et al., 2005). Consequently, a 
possible neuroprotective strategy is the control of the levels of adenosine by manipulation of 
adenosine kinase activity (Gouder N et al., 2004). This enzyme acts as key sensor and regulator of 
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ambient adenosine and can play a pivotal role in fine-tuning glutamatergic and dopaminergic 
neurotransmission, based on adenosine’s activation of its receptors with opposing activities (A1 
versus A2A) (Boison D, 2008). Gouder and collaborators reported that inhibition of adenosine 
kinase (thus increasing extracellular endogenous adenosine) effectively decreased chronic 
convulsive behavior, in an animal model of epilepsy (Gouder N et al., 2004). Increasing 
extracellular adenosine could be considered a suitable therapeutic target to obtain neuroprotection in 
other brain conditions besides epilepsy, such as ischemia (Pignataro G et al., 2007), stroke 
(Kowaluk EA et al., 1998; Boison D, 2006), chronic pain (McGaraughty S and Jarvis MF, 2006) or 
schizophrenia (Lara DR et al., 2006). However, pharmacological manipulation of adenosine kinase 
activity can lead to the appearance of severe side effects (Ugarkar BG et al., 2000; Gouder N et al., 
2004). It has already been suggested that adenosine kinase is effective mainly under physiological 
conditions; whereas, in pathological states, when extracellular level of adenosine is increased, 
adenosine deaminase seems to play a pivotal role. It has been shown that 2-deoxycoformycin; an 
inhibitor of adenosine deaminase prevents histological changes in the hippocampus by decreasing 
the infarct area and neuronal degeneration in global forebrain ischemia in rats and gerbil (Wardas J 
et al., 2002). A1 receptors can play a role in neuroprotection since their activation decreases 
glutamate release and hyperpolarize neurons which are found to be responsible for ischemia-
induced cell death (Gerber U and Gahwiler BH, 1994; Cunha RA, 2005). Adensine A1 receptors 
may provide protection by acting via pre and post-synaptic receptors. When adenosine is released it 
acts on presynaptic A1 receptors and may attenuate the influx of Ca2+ thorugh voltage-dependent 
calcium channels and thus decrease the release of glutamate. By inhibiting this release, adenosine 
decreases the excitability of NMDA receptors and as a consequence hinders the NMDA - mediated 
Ca2+ influx to neurons, the latter being the major mechanism that underlies neuroprotection. 
Another putative mechanism of the neuroprotective action of adenosine is related to postsynaptic 
adenosine A1 receptors. By stimulating postsynaptic A1 receptors, adenosine counteracts excessive 
membrane depolarization by the activation of K+ channels and increases in the efflux of K+, which 
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leads to hyperpolarization of postsynaptic neurons. As consequence, adenosine A1 receptor 
stimulation diminishes the opening of voltage-dependent Ca2+ channels and neuronal Ca2+ influx. 
By antagonizing membrane depolarization, adenosine elevates the threshold for the opening of the 
NMDA receptor - operated channels, which possibly contributes to its neuroprotective action. 
Therefore, by stabilizing membrane potentials and maintaining intracellular Ca2+ homeostasis in 
postsynaptic neurons, adenosine may act as a neuroprotector (Wardas J et al., 2002).  
 
Figure 10: Schematic representation of possible mechanism responsible for the neuroprotective 
action of adenosine A1 receptor agonist (AKA – adenosine kinase, ADE – adenosine deaminase) 
(Wardas J et al., 2002). 
 
Thus it has been described that A1 receptor agonists and antagonists consistently attenuate 
and potentiate brain damage, respectively (de Mendonça A et al., 2000). However, the use of A1 
receptor agonists as a neuroprotective strategy has several disadvantages, namely the occurrence of 
prominent cardiovascular effects (Olsson RA and Pearson JD, 1990; Shryock JC and Belardinelli L, 
1997), the poor brain permeability of A1 receptor agonist and their short “window of opportunity” 
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(Cunha RA, 2005). Given that chronic noxious stimuli cause a down-regulation of A1 receptor and 
an up-regulation of A2A receptor, there is a trend to emphasise the interest of A2A receptor compared 
to A1 receptor in neuroprotection (Cunha RA, 2005). In fact, chronic stressful stimuli cause an 
increased expression and density of A2A receptor in animal models of Parkinson’s disease (Pinna A 
et al., 2002), of epilepsy (Rebola N et al., 2005a), diabetes (Duarte JM et al., 2006) or restraint 
stress (Cunha GS et al., 2006). Most notably, A2A receptor antagonists confer neuroprotection in 
several pathological conditions in adult animals such as upon ischemia (Monopoli A et al., 1998; 
Chen JF et al., 1999), or excitotoxicity (Jones A et al., 1998; Behan W and Stone TW, 2002). In 
humans there is an inverse association between caffeine consumption and Parkinson’s (PD) disease 
(Ross GW et al., 2000). A2A receptor antagonists are currently being developed as anti-parkinsonian 
drugs, since they are claimed to provide a double benefit: 1) symptomatically they prevent motor 
dysfunction; 2) they also provide neuroprotection (Chen JF et al., 2007). In fact, caffeine and other 
A2A receptor antagonists provide functional protection against dopaminergic neurotoxicity and also 
reduce degeneration of the dopaminergic system in the MPTP model of PD (Chen JF et al., 2001; 
Xu K et al., 2002). Chen and colleagues reported that A2A receptor - mediated control of 
psychomotor function and neuroprotection involves distinct cellular mechanisms, using forebrain 
neuronal-specific A2A receptor knockout mice (Yu L et al., 2008). A2A receptor activity in forebrain 
neurons is critical for control of psychomotor activity, but not for neuroprotection against brain 
injury, which might indicate a role of A2A receptor in glial cells (Yu L et al., 2008). At this moment 
there is no consensus about the mechanisms by which A2A receptor blockade confer a robust 
neuroprotection in noxious situations. Two leading hypotheses are currently being explored to 
explain the neuroprotection afforded by A2A receptor blockade: control of glutamate excitotoxicity 
and control of neuroinflammation (Cunha RA, 2005). 
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1.11. Adenosine and neuroinflammation 
Neuroinflammation is present in different conditions of brain damage and is a double-edged 
sword, possibly contributing for brain damage, but also for the repair and regeneration of brain 
tissue (Schwartz M and Moalem G, 2001).  Adenosine is an endogenous purine nucleoside that is 
generated at sites that are subjected to ‘stressful’ conditions. Adenosine modulates a variety of glial 
functions, thus indirectly affecting neurons viability. Both microglia and astroglia cells are endowed 
with all known adenosine receptors that respond to changes in extracellular adenosine caused by 
traumatic and chemical insults with morphological and biochemical changes. However, the effects 
of adenosine on glial cells depends on various factors: the signaling pathway coupled to the specific 
receptor involved, the respective density of the receptor subtype (which may be subject of changes 
due to glial activation) and the respective affinity of the receptor for endogenous adenosine.  
 
1.11.1. Effects of adenosine on astroglia 
In response to noxious stimuli to the CNS, astrocytes undergo a process of proliferation, 
morphological change (hypertrophy of cell bodies, thickening and elongation of astrocytic 
processes) and increase the expression of glial fibrillary acidic protein. This process, which is 
termed astrogliosis, is associated with enhanced release of growth factors and neurotrophins that 
support neuronal growth but might also lead to the formation of neuronal scars (Liberto CM. et al., 
2004).  Astrocytes express all four subtypes of adenosine receptor, stimulation of which modulates 
various astrocyte functions. Adenosine acts at high affinity A1 receptors to reduce astrocyte 
proliferation (Rathbone MP. et al., 1991).  By contrast, increased occupancy of A2A receptors, 
which is expected to occur following up regulation of this receptor secondary to hypoxia, trauma 
and inflammation (Cunha RA. 2005), increases astrocyte proliferation and activation (Brambilla R. 
et al 2003). This indicates that adenosine might be a key factor in inducing astrogliosis following 
ischemic events. Adenosine at high concentrations induces astrocyte cell death by apoptosis in 
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vitro, via mechanisms involving both the activation of the A3 receptor and adenosine internalization 
and metabolism (Dare E et al., 2007). 
 
Figure 11: Regulation of astrocyte proliferation and apoptosis by adenosine receptors. (Hasko G et 
el., 2007) 
 
In addition to regulating the proliferation and survival of astrocytes, adenosine has potent 
effects on the secretory functions of these cells. Stimulation of A1 receptors causes the release of 
nerve growth factor (NGF) (Ciccarelli R. et al., 1999) and, thus, appears to have an important role 
in supporting neuronal survival and growth. A2A receptor stimulation inhibits the expression of 
inducible nitric oxide synthase (iNOS), and thus the production of nitric oxide (NO), by astrocytes. 
The production of NO by iNOS in the brain seems to contribute to the pathophysiology of many 
CNS diseases (Licinio J. et al., 1999), so the inhibition of NO formation by adenosine might be an 
important protective mechanism during inflammatory conditions in the brain. Finally, A3 receptor 
stimulation induces the synthesis of a neuroprotective chemokine called chemokine (C-C motif) 
ligand 2 (CCL2; known formerly as monocyte chemoattractant protein 1) by astrocytes 
(Wittendorp, MC. et al., 2004). Taken collectively, adenosine appears to alter astrocyte function in 
ways that are consistent with a neuroprotective role. Nevertheless, adenosine might also aggravate 
tissue injury by inducing excessive astrogliosis. It should be remembered that astrocytes are an 
important component of the blood brain barrier (BBB) and are directly involved in the control of the 
BBB permeability via release of mediators. Recent experiments performed with an experimental 
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BBB in vitro model have not supported the hypothesis of a major role of adenosine receptor 
subtypes in the regulation of BBB permeability (Dare E et al., 2007). 
 
1.11.2. Effects of adenosine on microglia 
Microglia the immunocompetent cells of the central nervous system, react to chemical and 
structural changes in their environment with morphological and biochemical changes, switching 
from a silent ramified state to an active phagocytosing macrophage like phenotype (Stoll G. et al., 
1999). Most neurological disorders involve activation and, possibly, dysregulation of microglia. 
Microglia expresses A1 receptors, A2A receptors and A3 receptors, but there is no evidence that they 
contain A2B receptors. Adenosine stimulates the proliferation of naive microglial cells through a 
mechanism that involves the simultaneous stimulation of A1 receptors and A2 receptors. Although 
the proliferation and/or apoptosis of microglia are regulated by several adenosine receptors, the 
secretion activity of these cells appears to be stimulated by A2A receptors. For example, A2A 
receptor stimulation up regulates cyclooxygenase 2 (COX-2) and the release of prostaglandin E2 
(PGE2), which might indicate a proinflammatory role of A2A receptor stimulation (Feibich BL. et 
al., 1996). Furthermore, A2A receptor activation induces the synthesis and release of NGF (Heese, 
K. et al., 1997). Interestingly recent finding by Orr AG et al., (2010) showed that A2A receptors are 
expressed on microglia specifically when they are activated. They reported that A2A receptor 
stimulation causes decrease in ramification of microglia and thus activation of microglia. Also A2A 
receptor stimulation retracts microglia from injury site. Although microglia contains A3 receptors, 
the stimulation of which results in increased phosphorylation of extracellular signal-regulated 
kinase 1, 2 (ERK1, 2) (Hammarberg C. et al., 2003), the role of A3 receptor stimulation in 
regulating microglial function is unclear. In summary, adenosine appears to have both pro-
inflammatory and anti-inflammatory effects, and it is difficult to provide a clear picture of how 
adenosine affects microglial functions.  
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2. Aims of the study  
2.1. Effect of caffeine on MDMA induced neurotoxicity 
  3, 4 methylendioxymethamphetamine (MDMA, ecstasy) is a popular recreational drug. 
Ecstasy tablets are often taken with caffeinated beverages or contaminated with caffeine in varying 
amounts. Previous studies showed that caffeine enhances hyperthermia and tachycardic response 
induced by MDMA in rats (Mc Namara N et al., 2006, 2007). Also studies by Camarasa et al., 
(2006) found potentiation of MDMA induced decrease in number of serotonergic transporter level 
by caffeine. Microglial and astroglial activation plays an important role in neurotoxicity and 
represent an early step in MDMA-induced neurotoxicity (Thomas et al., 2004; Zhang et al., 2006). 
During my PhD training i have studied whether association of caffeine at dose equivalent to those 
consumed by human with MDMA affects MDMA - induced hyperthermia, neuroinflammatory and 
neurotoxic effects toward dopaminergic neurons in mice.  
To pursue this objective, the following experiments were carried out: 
● Assessment of inflammatory response in SNc and striatum studied through analysis of GFAP and 
CD11b immunohistochemistry as markers of astroglia and microglia. 
● Assessment of dopaminergic neuronal damage in SNc studied by tyrosine hydroxylase (TH) 
immunohistochemistry.  
● Modification in MDMA induced hyperthermia assessed by measuring rectal temperature. 
 
2.2. Effect of A1/A2A receptor antagonists on MDMA induced neurotoxicity 
In the first part of the study we showed that caffeine a non-specific adenosine A1 and A2A 
receptor antagonist enhances MDMA induced microglial and astroglial activation in mice striatum 
(Khairnar et al., 2010). In order to evaluate involvement of A1 and A2A receptors in caffeine 
modulation of MDMA-effects we searched for the effect of selective adenosine A1 and A2A receptor 
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antagonists on MDMA induced gliosis in SNc and striatum. Moreover we evaluated dopaminergic 
neuronal damage after MDMA in the substantia nigra pars compacta (SNc) and the influence of A1 
and A2A receptor antagonists on this event. We also tested the effect of these adenosine receptor 
antagonists on MDMA induced hyperthermia since several studies have correlated this effect with 
MDMA induced neurotoxicity (Camarasa et al., 2006; Mc Namara et al., 2006; Vanattou-saifoudine 
N et al., 2010). 
To pursue this objective, the following experiments were carried out: 
● Assessment of inflammatory response in SNc and striatum studied through analysis of GFAP and 
CD11b immunohistochemistry as markers of astroglia and microglia. 
● Assessment of dopaminergic neuronal damage in SNc studied by tyrosine hydroxylase (TH) 
immunohistochemistry.  
● Modification in MDMA induced hyperthermia assessed by measuring rectal temperature. 
 
The results of the present study provide important insights to mechanism involved in increasing 
MDMA induced glial activation by caffeine. 
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3. Material and Methods 
3.1. Drugs 
MDMA–HCl (synthesized by Prof. Plumitallo Department of Pharmaceutical Chemistry and 
Technology, University of Cagliari) was dissolved in saline. Caffeine (Sigma–Aldrich, Milan, Italy)  
was dissolved in water, DPCPX (Sigma–Aldrich, Milan, Italy) was suspended in 0.5% Tween 80; 
SCH 58261 (kindly provided by Prof. Baraldi, Ferrara) was suspended in 0.5% Methyl cellulose. 
 
3.2. Animals 
Adult male C57BL/6J mice, 3 months old (20–25 g; Charles River, Milan, Italy) were 
maintained at a constant temperature (21 ± 1°C) in 12-h light/dark cycles (lights on at 08:00), and 
given food and water ad libitum. All experimental procedures were carried out in accordance with 
the European Communities Council Directive of 24 November 1986 (86/609/EEC) and approved by 
the ethics committee of the University of Cagliari. 
 
3.3. Treatment 
Mice received repeated administrations of vehicle or MDMA (4 x 20 mg/kg, 
intraperitoneally, (i.p)) at 2 h intervals alone or in combination with Caffeine (10mg/kg, i.p.), SCH 
58261 (0.5 mg/kg, i.p.) or DPCPX (0.5 mg/kg, i.p.) 30 min before the first and third administration 
of MDMA. On second day, mice received two administrations of Caffeine, SCH 58261, DPCPX or 
saline at 12 h interval and on third day one further administration. Mice were sacrificed 48 h after 
last administration of MDMA for immunohistochemical studies. 
 
3.4. Immunohistochemistry 
Animals were anaesthetized with chloral hydrate (450mg/kg, i.p.) and perfused with 4% 
paraformaldehyde in phosphate buffer 0.1 M (pH 7.4). Brains were isolated and kept in fixing 
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solution for 2h and later in PBS plus sodium azide. Coronal sections (50 µm thick) of mice brain 
were cut on a vibratome and immunostained for tyrosine hydroxylase (TH), glial fibrillary acidic 
protein (GFAP) and CD11b in order to analyze dopaminergic neuronal damage, astroglial and 
microglial activation respectively. Immunohistochemistry was carried out in free-floating sections 
with standard avidin–biotin (ABC; Vector Laboratories, UK) immunohistochemical protocols. 
Sections were treated with hydrogen peroxide to block endogenous peroxidases and then incubated 
overnight with the following specific primary antisera: polyclonal rabbit anti-TH (1:1000, Biomol), 
monoclonal mouse anti-GFAP (1:400; Sigma–Aldrich) and monoclonal rat anti-CD11b (1:1000; 
Serotec, UK). For visualization it was used 3, 3 - diaminobenzidine as chromogen. After getting 
colour these sections were mounted on chromealum-gelatine coated slides dried and dehydrated 
with 70%, 96% and 100% ethanol.  
 
3.5. Image Analysis 
Images were captured under constant light conditions using a PixeLink PL-A686 camera at 
10X magnification for the SNc and at 20X magnification for the striatum. For each animal, three 
sections from the SNc (A = -2.92, -3.28, -3.64 mm from bregma, according to Mouse brain Atlas by 
Paxinos and Franklin 2001), and three sections from striatum (A = 1.10, 0.74, 0.38 mm from 
bregma), were analyzed for each protein evaluated in the study. 
GFAP immunoreactivity in the SNc was quantified by counting the number of positive cells 
in the entire left and right part of this structure. For quantification of GFAP immunoreactivity in the 
striatum, one dorsolateral and one ventromedial portion were analyzed from both the left and right 
parts using PixeLink image analysis software. Analysis of CD11b immunoreactivity in the SNc and 
striatum was done with the analysis software SCION Image (Scion Corporation, Frederick, MD, 
USA). Within each frame, the area occupied by gray values above the threshold was automatically 
calculated. 
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In order to obtain averages for GFAP and CD11b, values were normalized with respect to 
vehicle. All values were expressed as mean ± SEM and were statistically analyzed with a one-way 
ANOVA followed by the Newman–Keuls post hoc test. 
 
3.6. Stereological quantification of TH-immunoreactive neurons 
TH-immunoreactive (TH-ir) neurons in the substantia nigra pars compacta (SNc) were 
quantified in both hemispheres of each brain using the stereological principles as described 
previously (Ossowska et al., 2005). Systemic uniform random sampling was used to choose the 
sections. The first sampling item was taken at random from the frontal part of the substantia nigra 
(ca. -2.80 mm from the bregma according to Paxinos and Franklin, 2001) and all the remaining 
sampling items were taken at a fixed distance from the previous one. At least 5–6 sections through 
the entire length of the substantia nigra were sampled. All stereological counting procedures were 
performed using a microscope (Leica, DMLB; Leica, Denmark) equipped with a projecting camera 
(Basler Vision Technologies, Germany) and a microscope stage connected to an xyz stepper 
(PRIOR ProScan) controlled by a computer using the new CAST Visiopharm (Denmark) software. 
The SNc region was carefully outlined under lower magnification (5x) and its volume was 
estimated using Cavalieri’s principle (Gundersen and Jensen, 1987). The total number of TH-ir 
neurons was unbiasedly estimated under higher magnification (63x) using randomized meander 
sampling and optical dissector method. TH-ir neurons were counted only when present completely 
or partially inside the frame and when they did not touch any of the red exclusion lines. Neurons 
which touched green inclusion lines were counted. The cut thickness of sections was 50 µm and the 
optical dissector height was 12 µm. The top (13 µm) and bottom (25 µm) layers that shrunk during 
staining procedure were discarded. In each sampled area the dissector position was adjusted. The 
sampling area covered 20% of the region of interest. The counting frame (8302, 8 µm2) applied the 
exclusion and inclusion lines and unbiased counting was performed by an experimenter blinded to 
the treatment. The results are presented as the mean ±SEM from 4-6 mice per each group. 
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4. Results  
4.1. Inflammatory response in SNc and striatum 
4.1.1. GFAP Immunoreactivity in the Striatum and SNc 
GFAP immunoreactivity was low in both the striatum and SNc in the basal condition (Fig. 
8.1, 8.2, 8.6 and 8.7). It was significantly higher in the striatum after treatment with MDMA (20 
mg/kg, i.p.), MDMA plus caffeine (10mg/kg, i.p.), MDMA plus SCH58261 (0.5mg/kg, i.p.) and 
MDMA plus DPCPX (0.5 mg/kg, i.p.) compared with vehicle (P < 0.001) (Fig 8.1, 8.6A and 8.6B). 
Post hoc analysis indicated that administration of DPCPX and Caffeine in MDMA-treated mice was 
associated with significantly higher GFAP immunoreactivity in the striatum (Fig. 1 and 6B) 
compared with mice treated only with MDMA (P < 0.001) whereas administration of SCH58261 in 
MDMA treated mice did not altered GFAP immunoreactivity in striatum (Fig 6A). Treatment with 
MDMA, MDMA plus Caffeine, MDMA plus DPCPX and MDMA plus SCH 58261 did not alter 
GFAP immunoreactivity in the SNc compared with vehicle (Fig. 8.2 and 8.7). Caffeine, SCH 58261 
and DPCPX alone did not modify GFAP both in striatum and SNc (data not shown). 
 
4.1.2. CD11b Immunoreactivity in the Striatum and SNc 
Similar, to GFAP, CD11b immunoreactivity was low in both the striatum and SNc in the 
basal condition (Fig. 8.3, 8.4, 8.8 and 8.9). It was significantly higher in both striatum (Fig. 8.3, 
8.8A and 8.8B) and SNc (Fig. 8.4 and 8.9) after treatment with MDMA (20 mg/kg, i.p.), MDMA 
plus caffeine (10 mg/kg, i.p.), MDMA plus SCH58261 (0.5 mg/kg, i.p.) and MDMA plus DPCPX 
(0.5 mg/kg, i.p.)  compared with vehicle (P < 0.05). Post hoc analysis indicated that administration 
of SCH58261 in MDMA-treated mice was associated with significantly higher CD11b 
immunoreactivity in the striatum and in the SNc as compared to mice treated only with MDMA (P 
< 0.05) (Fig 8A and 9A) in contrast caffeine and DPCPX potentiated CD11b immunoreactivity only 
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in striatum (P < 0.05) but not in SNc (Fig. 8.3,8.8B and 8.9B). Caffeine, SCH58261 and DPCPX 
alone did not modify CD11b levels both in striatum and SNc (data not shown). 
4.2. Neuronal damage in SNc 
4.2.1. TH Immunoreactivity in SNc 
Repeated administration of MDMA (20 mg/kg, i.p.), MDMA plus caffeine (10mg/kg, i.p.), 
MDMA plus SCH58261 (0.5mg/kg, i.p.) and MDMA plus DPCPX (0.5mg/kg, i.p.) significantly 
decreased number of TH immunopositive cells compared with vehicle in SNc (P < 0.05) (Fig. 8.5 & 
8.10). Post hoc analysis indicated that treatment with caffeine (10mg/kg, i.p.), SCH58261 (0.5 
mg/kg, i.p.), and DPCPX (0.5 mg/kg, i.p.) in MDMA treated mice did not further decreased number 
of TH immunopositive cells as compared to MDMA treated mice.  
 
4.3. MDMA induced hyperthermia 
Repeated administration of MDMA (20 mg/kg, i.p.), MDMA plus caffeine (10mg/kg, i.p.), MDMA 
plus SCH58261 (0.5mg/kg, i.p.) and MDMA plus DPCPX (0.5mg/kg, i.p.) induced significant 
increase in rectal temperature as compare to vehicle treated mice (P < 0.05) (Fig. 8.11 & 8.12). Post 
hoc analysis indicated that treatment with caffeine (10mg/kg, i.p.), SCH58261 (0.5 mg/kg, i.p.), and 
DPCPX (0.5 mg/kg, i.p.) in MDMA treated mice did not further increased rectal temperature as 
compare to MDMA treated mice.  
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5. Discussion 
The results of the present study showed that acute repeated administration of MDMA 
induced a neuroinflammatory process in mice, characterized by microgliosis in the striatum and 
SNc and astrogliosis in the striatum of mice. Caffeine, when given together with MDMA, 
potentiated the activation of microglia and astroglia in the striatum. Caffeine is a safe substance 
present in beverages such as coffee, tea, soft drinks, and energy drinks. However, as shown by the 
present study, caffeine taken with MDMA at doses similar to those that may be taken for 
recreational use with energy drinks may exacerbate MDMA neuroinflammation posing serious 
health consequences for consumers of this drug of abuse.  
As caffeine is non-specific A1/A2A receptor antagonist we also tested influence of specific 
A1 and A2A receptor antagonists on MDMA induced gliosis in a separate set of experiment. We 
found that treatment with the A2A receptor antagonist SCH58261 potentiated MDMA - induced 
microgliosis in both the striatum and SNc, in contrast, the A1 receptor antagonist DPCPX 
potentiated both microgliosis and astrogliosis in striatum but not in SNc. Thus the results of the 
present study indicate a role of adenosine A1 receptor in the modulation of both astroglia and 
microglia induced by MDMA, whereas A2A receptors modulate MDMA-induced microglia only, 
indicating that
 
antagonism of A1 receptors better correlates to the effect of caffeine. Moreover, 
while both adenosine receptors are involved in neuroinflammatory effects neither treatment with 
caffeine nor A1 and A2A receptor antagonism interfere with MDMA-induced dopamine neuron 
degeneration and hyperthermic effect. 
Adenosine is an important neuromodulator whose concentration increases in the presence of 
acute and chronic brain insults with a preferential activation of A1 or A2A receptors at low or high 
adenosine levels respectively (Cunha RA. 2005). Glial cells are endowed with adenosine receptors 
and depending on the type of insult, whether it is acute or chronic, specific adenosine A1 or A2A 
receptors are stimulated producing either proinflammatory or anti-inflammatory effect (Cunha RA. 
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2005). In the presence of an acute insult, the adenosine A1 receptor, which is stimulated at lower 
levels of adenosine, reduces production of inflammatory cytokines and the increase of free radicals 
by inhibiting astrocyte proliferation (Cunha RA. 2005, Hasko et al., 2005). Moreover, stimulation 
of the A1 receptor enhances production of important neuroprotective substances, such as NGF, 
TGF-β1 and S100 β, in cultured astrocytes (Dare E et al., 2007). In addition, microglial cell 
activation was enhanced in A1 receptor null mice and A1 receptor deficiency increased 
proinflammatory responses (Tsutsui S et al., 2004). Thus we may hypothesize that caffeine and 
DPCPX after acute administration of MDMA by antagonizing the effect of adenosine A1 receptors, 
may potentiate MDMA induced astrogliosis and microgliosis in mice striatum. 
Similarly to the A1, the A2A receptors on glial cells exerts complex actions on 
neuroinflammation, however, differently from A1 receptors, A2A receptors have been found in 
microglia cells whereas their presence in astroglia cells and their control in astrogliosis is 
controversial (Melani A et al., 2009; Brambilla R et al.,2003; Fiebich BL et al., 1996; Alloisio S 
2004). Recent findings by Orr AG et al., (2010) showed that A2A receptor stimulation retracts 
microglia from injury site and inhibits activation of microglia, thus antagonists may increase it 
which is in line with the present findings where A2A receptor antagonist potentiated MDMA 
induced microglial activation. Our results by showing that A2A receptor antagonism affects 
microglia but not astroglia activation evidence the inability of A2A receptors to control astrogliosis 
and suggest that the A2A receptor needs to act in concert with the A1 receptor to trigger astrogliosis. 
Interestingly, previous results by Brambilla R et al., (2003) have shown the inability of A2A receptor 
alone to control astrogliosis in cell culture. 
Previous studies by Granado N et al., 2008 reported that MDMA given in similar doses and 
regimen produced dopaminergic neuronal damage in the SNc of mice. Similarly, the current study 
shows a decrease in the number of TH- immunoreactive neurons in SNc after MDMA, however, 
neither treatment with caffeine nor with SCH58261 and DPCPX further decreased these TH-ir 
neurons in SNc.  
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An important interplay in neuron/glia communication and in neurotoxicity is played by glutamate 
whose release is controlled by adenosine A1 and A2A receptors in an opposite way. In addition 
several studies (Blum D et al., 2003; Li Y et al., 2006; Dai SS et al., 2010) demonstrate a dual role 
of A2A receptors on neuroinflammation depending on the levels of glutamate. At low glutamate 
concentration, stimulation of A2A receptors attenuated brain damage by inhibiting inflammatory 
cytokines expression and iNOS activity. In contrast A2A receptor activation worsens inflammatory 
effects at high glutamate concentration (Dai SS et al., 2010). However, glutamate release is not 
supposed to be involved in MDMA neurotoxicity in mice (Colado MI et al., 2001, Quinton MS et 
al., 2006) and therefore actions on receptors controlling its release do not appear to influence 
MDMA induced neurotoxicity.   
The results of the present study show that although A1 and A2A receptor blockade increase 
glial activation induced by MDMA, it does not actually worsen dopamine neuron degeneration 
induced by MDMA suggesting that adenosine receptor blockade might increase neuron 
vulnerability without favoring overt neurotoxicity.  
MDMA induces consistent hyperthermia in rats though much more variable responses have 
been seen in mice (Green AR et al., 2003). Moreover, it has been reported that pretreatment with 
caffeine in MDMA-treated rats increases hyperthermia (McNamara R et al., 2006) and SCH58261 
but not DPCPX is involved in potentiating MDMA induced hyperthermia by caffeine in the same 
species (Vanattou-Saïfoudine N et al., 2010).  
An increase in body temperature has been suggested to be a contributing factor to MDMA-
induced toxicity (Mc Namara R et al., 2006), it is therefore of particular interest that in the present 
study while a significant increase in temperature with MDMA was observed, neither caffeine nor 
SCH58261 and DPCPX further increased MDMA induced hyperthermia and dopamine neuron 
degeneration although they increased gliosis. This result may therefore suggest that while increase 
in body temperature may be necessary for potentiation of neurotoxic effects by MDMA, increase in 
neuroinflammatory effects appears to not be correlated with changes in this parameter.  
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The reason of the discrepancy between our results and those on adenosine A2A receptor 
involvement in hyperthermia induced by caffeine in the presence of MDMA (Vanattou-Saïfoudine 
N et al., 2010), might be due to the different species used in the two studies (rats versus mice) 
which have different susceptibility to temperature changes by MDMA (Green AR et al., 2003). On 
the other hand in the same report Vanattou-Saïfoudine N et al., (2010) reported that caffeine 
provokes a dopamine D1-receptor dependent exacerbation of MDMA-induced hyperthermia, 
suggesting that caffeine promotes post-synaptic D1 receptor-dependent responses and that MDMA-
induced neurotoxicity and hyperthermia are associated to dopamine D1 responses. 
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6. Conclusions 
Co-administration of MDMA and caffeine has been suggested to interact at the level of metabolism 
(through CYP1A2) or processes like absorption, distribution or elimination, although an interaction 
between the two substances at the level of catecholamine and serotonin has been envisaged as the 
main mechanism of interaction (Vanattou-Saifoudine N et al., 2010). The results of our study 
provide an important knowledge on the role of the specific adenosine receptor subtypes involved in 
modulatory effect of caffeine on MDMA-induced neuroinflammatory responses. Thus evidencing 
that the interaction existing between MDMA and caffeine in the mediation of glial activation but 
not dopamine neuron degeneration or hyperthermia in mice are due to an action on specific 
adenosine A1 and A2A receptors, although antagonism of A1 receptor better correlates to 
potentiation of MDMA induced glial activation by caffeine.  
These findings may be important to address clinical investigations of potential severe side effects 
associated with the combined use of caffeine and MDMA in humans.  
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8. Figures 
Effect of caffeine on MDMA induced GFAP (Astroglia)  
immunoreactivity in striatum 
 
 
 
 
 
Figure 8.1: Effect of repeated administration of MDMA (20mg/kg, i.p.) and caffeine (10mg/kg, i.p.) 
on astroglial activation, using GFAP immunoreactivity as a marker. Representative images and 
histogram from the striatum immunostained for GFAP. Values are reported as a percentage of 
GFAP-positive cells with respect to vehicle-treated mice and are expressed as mean ± SEM. *P < 
0.001 versus vehicle treated group;  #P < 0.001 versus the group treated with MDMA alone.  
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Effect of caffeine on MDMA induced GFAP (Astroglia) 
immunoreactivity in SNc 
 
 
 
 
Figure 8.2: Effect of repeated administration of MDMA (20mg/kg, i.p.) and caffeine (10mg/kg, i.p.) 
on astroglial activation, using GFAP immunoreactivity as a marker. Representative images and 
histogram from the substantia nigra pars compacta (SNc) immunostained for GFAP. Values are 
reported as a percentage of GFAP-positive cells with respect to vehicle-treated mice and are 
expressed as mean ± SEM.  
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Effect of caffeine on MDMA induced CD11b (Microglia) 
immunoreactivity in striatum 
 
 
 
 
Figure 8.3: Effect of repeated administration of MDMA (20mg/kg ,i.p.) and caffeine (10mg/kg, i.p.) 
on microglial activation, using CD11b immunoreactivity as a marker. Representative images and 
histogram from the striatum immunostained for CD11b. The area occupied by gray values above a 
threshold is calculated and expressed as square pixels and as a percentage of staining in vehicle-
treated mice and values are expressed as mean ± SEM. *P < 0.05 versus vehicle treated group;  #P < 
0.05 versus the group treated with MDMA alone.  
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Effect of caffeine on MDMA induced CD11b (Microglia)  
immunoreactivity in SNc 
 
 
 
 
 
Figure 8.4: Effect of repeated administration of MDMA (20mg/kg, i.p.) and caffeine (10mg/kg, i.p.) 
on microglial activation, using CD11b immunoreactivity as a marker. Representative images and 
histogram from the SNc immunostained for CD11b. The area occupied by gray values above a 
threshold is calculated and expressed as square pixels and as a percentage of staining in vehicle-
treated mice and values are expressed as mean ± SEM. *P < 0.05 versus vehicle treated group 
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Effect of caffeine on MDMA induced TH  
immunoreactivity in SNc 
 
 
 
 
Figure 8.5: Effect of repeated administration of MDMA (20mg/kg, i.p.) and caffeine (10mg/kg, i.p.) 
on dopaminergic neuronal damage, using TH immunoreactivity as a marker. Representative images 
and histogram from the SNc immunostained for TH. Values are reported as a percentage of TH 
immune positive neurons with respect to vehicle treated mice and values are expressed as mean ± 
SEM. *P < 0.05 versus vehicle treated group.  
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Effect of SCH58261 & DPCPX on MDMA induced GFAP (Astroglia) 
immunoreactivity in striatum 
 
 
A) SCH58261                                                       B) DPCPX 
 
 
 
 
 
 
 
Figure 8.6: Effect of repeated administration of MDMA (20mg/kg, i.p.) and SCH58261 (0.5mg/kg, 
i.p.), DPCPX (0.5mg/kg, i.p.) on astroglial activation, using GFAP immunoreactivity as a marker. 
Representative images and histograms from the striatum immunostained for GFAP. Values are 
reported as a percentage of GFAP-positive cells with respect to vehicle-treated mice and are 
expressed as mean ± SEM. *P < 0.001 versus vehicle treated group;  #P < 0.001 versus the group 
treated with MDMA alone.  
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Effect of SCH58261 & DPCPX on MDMA induced GFAP  
immunoreactivity in SNc 
 
 
 
 
A) SCH58261                                                       B) DPCPX 
 
 
 
 
 
 
 
 
Figure 8.7: Effect of repeated administration of MDMA (20mg/kg,i.p.) and SCH58261 (0.5mg/kg,  
i.p.), DPCPX (0.5mg/kg, i.p.) on astroglial activation, using GFAP immunoreactivity as a marker. 
Representative images and histograms from the SNc immunostained for GFAP. Values are reported 
as a percentage of GFAP-positive cells with respect to vehicle-treated mice and are expressed as 
mean ± SEM. 
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Effect of SCH58261 & DPCPX on MDMA induced CD11b (Microglia) 
immunoreactivity in striatum 
 
 
 
A) SCH58261                                                       B) DPCPX 
 
 
 
 
 
 
 
Figure 8.8: Effect of repeated administration of MDMA (20mg/kg, i.p.) and SCH (0.5mg/kg, i.p.), 
DPCPX (0.5mg/kg, i.p.) on microglial activation, using CD11b immunoreactivity as a marker. 
Representative images and histograms from the striatum immunostained for CD11b. The area 
occupied by gray values above a threshold is calculated and expressed as square pixels and as a 
percentage of staining in vehicle-treated mice and values are expressed as mean ± SEM. *P < 0.05 
versus vehicle treated group;  #P < 0.05 versus the group treated with MDMA alone.  
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Effect of SCH58261 & DPCPX on MDMA induced CD11b (Microglia) 
immunoreactivity in SNc 
 
 
 
A) SCH58261                                                       B) DPCPX 
 
 
 
 
 
 
 
 
Figure 8.9: Effect of repeated administration of MDMA (20mg/kg, i.p.) and SCH (0.5mg/kg, i.p.), 
DPCPX (0.5mg/kg, i.p.) on microglial activation, using CD11b immunoreactivity as a marker. 
Representative images and histograms from the striatum immunostained for CD11b. The area 
occupied by gray values above a threshold is calculated and expressed as square pixels and as a 
percentage of staining in vehicle-treated mice and values are expressed as mean ± SEM. *P < 0.05 
versus vehicle treated group;  #P < 0.05 versus the group treated with MDMA alone.  
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Effect of SCH58261 & DPCPX on MDMA induced TH 
immunoreactivity in SNc 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.10: Effect of repeated administration of MDMA (20mg/kg,i.p.) and SCH58261 (0.5mg/kg, 
i.p.), DPCPX (0.5mg/kg, i.p.) on dopaminergic neuronal damage, using TH immunoreactivity as a 
marker. Representative images and histograms from the SNc immunostained for TH. Values are 
reported as a percentage of TH immune positive neurons with respect to vehicle treated mice and 
values are expressed as mean ± SEM. *P < 0.05 versus vehicle treated group.  
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Effect of caffeine on MDMA induced hyperthermia 
 
DRUGS Basal 
Temp 
1H MDMA 2H MDMA 3H MDMA 4H MDMA 
    Vehicle 35.525 ± 
0.2322 
34.875  ± 
0.1547 
34.675  ± 
0.2926 
34.525  ± 
0.3682 
34.90  ± 
0.2972 
MDMA 35.45 ± 
0.2179 
36.525 ± 
0.3682* 
37.125 ± 
0.3198* 
37.275 ± 
0.4607* 
36.5 ± 
0.2121* 
MDMA+CAFF 35.466 ± 
0.2458 
36.6166 ± 
0.2315# 
37.55 ± 
0.1522# 
37.5 ± 
0.1549# 
37.6333 ± 
0.1626# 
CAFFEINE 35.575 ± 
0.225 
35.7 ± 
0.1870 
35.35 ± 
0.3227 
35.275 ± 
0.3037 
35.85 ± 
0.1258 
 
 
 
 
 
 
 
 
 
Figure 8.11: Effect of repeated administration of MDMA (4 x 20mg/kg,i.p.) and caffeine (2 x 
10mg/kg, i.p.), on MDMA induced hyperthermia every one hour after MDMA administration. *P < 
0.05 versus vehicle treated group, #P < 0.05 versus vehicle treated group. 
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Effect of SCH58261 & DPCPX ON MDMA - induced hyperthermia 
DRUGS Basal 
Temp 
1H MDMA 2H MDMA 3H MDMA 4H MDMA 
Vehicle 36.125 ± 
0.1108 
35.8 ± 
0.1870 
35.925 ± 
0.1376 
35.6 ± 
0.1914 
35.575 ± 
0.075 
MDMA 36.05 ± 
0.1056 
37.416 ± 
0.0872* 
37.7 ± 
0.2129* 
37.933 ± 
0.1333* 
37.28 ± 
0.2182* 
MDMA+SCH58261 36.02 ± 
0.1067 
37.38 ± 
0.1685# 
37.76 ± 
0.1166# 
37.8 ± 
0.2073# 
37.56 ± 
0.1913# 
MDMA+DPCPX 36.16 ± 
0.1630 
37.26 ± 
0.16^ 
37.8 ± 
0.1449^ 
37.84 ± 
0.1503^ 
37.575 ± 
0.1648^ 
SCH58261 35.95 ± 
0.35 
36.5 ± 
0.00 
36.1 ± 
0.2 
36.2 ± 
0.1 
35.7 ± 
0.3 
DPCPX 35.9 ± 
0.4 
35.85 ± 
0.15 
35.95 ± 
0.15 
35.8 ± 
0.2 
35.85 ± 
0.45 
 
 
 
 
 
 
 
Figure 8.12: Effect of repeated administration of MDMA (4 x 20mg/kg,i.p.) and SCH58261 (2 x 
0.5mg/kg, i.p.), DPCPX (0.5mg/kg, i.p.) on MDMA induced hyperthermia every one hour after 
MDMA administration. *P < 0.05 versus vehicle treated group, #P < 0.05 versus vehicle treated 
group, ^P < 0.05 versus vehicle treated group.  
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Caffeine Enhances Astroglia and Microglia Reactivity Induced
by 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) in Mouse
Brain
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Abstract Several reports suggest that 3,4-methylene-
dioxymethamphetamine (MDMA) induces neurotoxic
effects and gliosis. Since recreational use of MDMA is often
associated with caffeinated beverages, we investigated
whether caffeine interferes with MDMA-induced astroglia
and microglia activation, thus facilitating its neurotoxicity.
MDMA (4 9 20 mg/kg) was acutely administered to mice
alone or in combination with caffeine (10 mg/kg). CD11b
and GFAP immunoreactivity were evaluated as markers of
microglia and astroglia activation in the substantia nigra
pars-compacta (SNc) and striatum. MDMA was associated
with significantly higher CD11b and GFAP immunoreac-
tivity in striatum, whereas only CD11b was significantly
higher than vehicle in SNc. Caffeine potentiated the increase
in CD11b and GFAP in the striatum but not in the SNc of
MDMA-treated mice. The abuse of MDMA is a growing
worldwide problem; the results of this study suggest that
combination of MDMA plus caffeine by increasing glial
activation might have harmful health consequences.
Keywords Glial cell  Adenosine  Drug of abuse 
Striatum  Psychostimulants
Introduction
The use of psychostimulant drugs is often combined
with beverages containing a high quantity of caffeine in order
to amplify their stimulant properties and reduce drowsi-
ness and fatigue. 3,4-Methylenedioxymethamphetamine
(MDMA)—known as ecstasy—is one of the most popular
psychostimulant whose neurotoxic effects on the central
nervous system are often debated. Specific neurotoxic dam-
age to 5-hydroxytryptamine and dopaminergic nerve endings
lasting for months in rodents and years in primates has been
demonstrated both biochemically and histologically (Green
et al. 2003; Granado et al. 2008). These neurotoxic effects
appear to result from free radical formation which in turn
induces oxidative stress process and from hyperthermia
(Green et al. 2003; Goni-Allo et al. 2008).
Evidence for the occurrence of MDMA-induced neuro-
toxic damage in human users, however, remains ambiguous
since such evidence is complicated by the fact that many
users often take other substances concomitantly, either
intentionally or due to impurities in ecstasy tablets. The
most popular of these associated substances is caffeine,
which, when given acutely, enhances the acute toxicity and
lethality of MDMA (McNamara et al. 2006).
Several findings have suggested that neuroinflammation
may play an active role in the pathogenesis of neurodegen-
erative diseases. Microglial and astroglial activation appear
to play an important role in neurotoxicity and MDMA-
induced toxicity is associated with microglial activa-
tion, which generates many reactive species (e.g., nitric
oxide, superoxide, cytokines) favouring neurodegeneration
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(Thomas et al. 2004). In this context it becomes of great
importance to investigate whether MDMA when given in
combination with caffeine, enhances astroglia or microglia
reactivity in experimental rodents.
The results of this study may bring important insights to
our knowledge of the toxic effects that may be caused by
the use of caffeine together with psychostimulant drugs.
Materials and Methods
Drugs
MDMA–HCl (synthesized by Prof. Plumitallo Department
of Pharmaceutical Chemistry and Technology, University
of Cagliari) was dissolved in saline. Caffeine (Sigma–
Aldrich, Milan, Italy) was dissolved in water.
Animals
Adult male C57BL/6J mice, 3 months old (20–25 g;
Charles River, Milan, Italy) were maintained at a constant
temperature (21 ± 1C) in 12-h light/dark cycles (lights on
at 08:00), and given food and water ad libitum. All
experimental procedures were carried out in accordance
with the European Communities Council Directive of 24
November 1986 (86/609/EEC) and approved by the ethics
committee of the University of Cagliari.
Treatment
Mice were treated with repeated administration of vehicle
(N = 6) or MDMA (4 9 20 mg/kg, intraperitoneally, i.p.)
(N = 12) at 2-h intervals alone or in combination with
repeated administration of vehicle or caffeine (2 9 10 mg/kg,
i.p.) (N = 16) 30 min before the first and third adminis-
tration of MDMA. On second day mice received two
administrations of vehicle or caffeine (10 mg/kg, i.p.) at
12 h interval and one administration on third day. Mice
were killed 48 h after the last administration of MDMA.
This dosing protocol of MDMA has been shown to produce
activation of microglial and astroglial cells (Thomas et al.
2004).
Immunohistochemistry
Animals were anaesthetized with chloral hydrate and per-
fused with 4% paraformaldehyde in phosphate buffer
0.1 M (pH 7.4). Coronal sections (50 lm thick) were cut on
a vibratome and immunostained for glial fibrillary acidic
protein (GFAP) and CD11b in order to analyze astroglial
and microglial activation, respectively. Immunohisto-
chemistry was carried out in free-floating sections with
standard avidin–biotin (ABC; Vector Laboratories, UK)
immunohistochemical protocols. Sections were treated
with hydrogen peroxide to block endogenous peroxidases
and then incubated overnight with the following specific
primary antisera: monoclonal mouse anti-GFAP (1:400;
Sigma–Aldrich) and monoclonal rat anti-CD11b (1:1000;
Serotec, UK). For visualization it was used 3,30-diam-
inobenzidine as chromogen. Images were captured under
constant light conditions using a PixeLink PL-A686 cam-
era at 109 magnification for the SNc and at 209 magni-
fication for the striatum. For each animal, three sections
from the SNc (A = -2.92, -3.28, -3.64 mm from
bregma, accordingly to Mouse brain Atlas by Paxinos and
Franklin 2001), and three sections from striatum
(A = 1.10, 0.74, 0.38 mm from bregma), were analyzed
for each protein evaluated in the study.
GFAP immunoreactivity in the SNc was quantified by
counting the number of positive cells in the entire left and
right part of this structure. For quantification of GFAP
immunoreactivity in the striatum, one dorsolateral and one
ventromedial portion were analyzed from both the left and
right parts using PixeLink image analysis software. Anal-
ysis of CD11b immunoreactivity in the SNc and striatum
was done with the analysis software Scion Image. Within
each frame, the area occupied by gray values above the
threshold was automatically calculated.
In order to obtain averages for GFAP and CD11b, values
were normalized with respect to vehicle.
All values were expressed as mean ± SEM and were
statistically analyzed with a one-way ANOVA followed by
the Newman–Keuls post hoc test.
Results
Previous studies have shown that expression of CD11b and
GFAP, markers of activated microglia and astroglia,
respectively, reached their maximum at 48 and 72 h after
MDMA administration (Granado et al. 2008; Thomas et al.
2004). Therefore, in our study, mice were killed 48 h after
last administration of MDMA in order to examine the
activation of both microglia and astroglia.
GFAP Immunoreactivity in the Striatum and SNc
GFAP immunoreactivity was low in both the striatum
and SNc in the basal condition (Fig. 1). It was signifi-
cantly higher in the striatum after treatment with MDMA
(20 mg/kg, i.p.) and MDMA plus caffeine (10 mg/kg, i.p.)
compared with vehicle (P \ 0.0001). Post hoc analysis
indicated that administration of caffeine in MDMA-treated
mice was associated with significantly higher GFAP
immunoreactivity in the striatum (Fig. 1a) compared with
436 Neurotox Res (2010) 17:435–439
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mice treated only with MDMA (P \ 0.0001). Treatment
with MDMA and MDMA plus caffeine did not alter GFAP
immunoreactivity in the SNc compared with vehicle
(Fig. 1b). Caffeine alone did not modify GFAP both in
striatum and SNc (data not shown).
CD11b Immunoreactivity in the Striatum and SNc
Similarly, to GFAP, CD11b immunoreactivity was low in
both the striatum and SNc in the basal condition (Fig. 2). It
was significantly higher in both the striatum (Fig. 2a) and
Fig. 1 Effect of repeated administration of MDMA (20 mg/kg, i.p.)
and caffeine (10 mg/kg, i.p.) on astroglial activation, using GFAP
immunoreactivity as a marker. Representative images and histograms
from the a striatum and b SNc, immunostained for GFAP. Values are
reported as a percentage of GFAP-positive cells with respect to
vehicle-treated mice and are expressed as mean ± SEM.
* P \ 0.0001 versus vehicle-treated group; # P \ 0.0001 versus the
group treated with MDMA alone. Scale bar: 50 lm. SNc substantia
nigra pars-compacta, SNr substantia nigra pars-reticulata
Fig. 2 Effect of repeated administration of MDMA (20 mg/kg, i.p.)
and caffeine (10 mg/kg, i.p.) on microglial activation, using CD11b
immunoreactivity as a marker. Representative images and histograms
from the a striatum and b SNc, immunostained for CD11b. The area
occupied by gray values above a threshold was calculated and
expressed as square pixels and as a percentage of staining in vehicle-
treated mice, and values are expressed as mean ± SEM. * P \ 0.02
versus vehicle-treated group, # P \ 0.05 versus the group treated with
MDMA alone. Scale bar: 50 lm. SNc substantia nigra pars-compacta,
SNr substantia nigra pars-reticulata
Neurotox Res (2010) 17:435–439 437
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SNc (Fig. 2b) after treatment with MDMA (20 mg/kg, i.p.)
and MDMA plus caffeine (10 mg/kg, i.p.) compared with
vehicle (P \ 0.05). Post hoc analysis indicated that
administration of caffeine in MDMA-treated mice was
associated with significantly higher CD11b immunoreac-
tivity in the striatum but not in the SNc compared with
mice treated only with MDMA (P \ 0.05). Caffeine alone
did not modify CD11b levels both in striatum and SNc
(data not shown).
Discussion
The results of the present study show that acute repeated
administration of MDMA induced a neuroinflammatory
process in mice, characterized by microgliosis in the stri-
atum and SNc and astrogliosis in the striatum. Moreover,
of great importance in terms of possible consequences in
humans is the finding that caffeine, when given together
with MDMA, potentiated the activation of microglia and
astroglia in the striatum.
Caffeine is a safe substance present in beverages such as
coffee, tea, soft drinks, and energy drinks. However, as
shown by the present study, caffeine taken with MDMA at
doses similar to those that may be taken for recreational use
with energy drinks may exacerbate MDMA toxicity posing
health consequences for consumers of this drugs of abuse.
Neuroinflammation is one of the factors responsible for
the pathogenesis of neurodegenerative disorders (Kers-
chensteiner et al. 2009). Studies have reported that
microglial and astroglial activation represent an early step
in MDMA-induced neurotoxicity and that within the
amphetamine class of drugs only those causing neurotox-
icity result in microglia activation (Thomas et al. 2004;
Granado et al. 2008).
Moreover, it is well-known that activation of glial cells,
particularly microglia, may contribute to neuronal damage
by the release of proinflammatory cytokines such as tumor
necrosis factor-a, interleukin-1b, and neurotoxic factors
that include reactive nitrogen species, reactive oxygen
species, and excitatory amino acids (Kerschensteiner et al.
2009), although a neuroprotective role of glial cells has
also been hypothesized (Merrill and Benveniste 1996). It
has also been shown that proinflammatory molecules such
as neuronal nitric oxide synthase (NOS) and inducible NOS
are increased 1 day after MDMA administration and that
their inhibition provides protection against MDMA-
induced dopamine loss in the striatum (Green et al. 2003).
Therefore, by showing higher activation of both microglia
and astroglia after MDMA plus caffeine compared with
MDMA alone, our results suggest that this drug combina-
tion may facilitate the neurodegenerative processes
induced by MDMA in mouse brain. Interestingly, studies
on MPTP model of Parkinson’s disease have shown that
striatal dopaminergic terminals are more vulnerable than
SNc cell bodies (Schmidt and Ferger 2001), being in line
with the higher glial activation in striatum observed in our
study.
One of the mechanisms implicated in MDMA neurotox-
icity is a hyperthermic response induced by the drug. Con-
sistent hyperthermia has been observed in rats and a
hyperthermic response, though much more variable, has
been seen in mice (Green et al. 2003; McNamara et al. 2006).
Moreover, promotion of temperature elevation by caffeine
was observed (McNamara et al. 2006), suggesting a possible
mechanism that may potentiate MDMA effects, contributing
to the increase in astroglia and microglia reactivity observed
after MDMA plus caffeine administration.
Caffeine affects the absorption of MDMA in intestinal
epithelial cells and increases the area under the plasma
concentration curve of MDMA (Kuwayama et al. 2007).
This effect, as well as hyperthermia, may have a role in
caffeine’s potentiation of MDMA effects (Green et al.
2003; Goni-Allo et al. 2008). A further consideration that
should be taken into account is that caffeine and MDMA
are extensively metabolized, and caffeine metabolites have
a long half-life. Therefore, the possibility that their
metabolites may have a role in glial activation cannot be
ruled out. Interestingly, however, it has been established
that caffeine does not inhibit CYP2D6, the enzyme
responsible for MDMA metabolism, and it did not alter the
half maximal inhibitory concentration for MDMA (Dow-
ney and O’Boyle 2007).
The results of the present study might seem to con-
tradict the results of studies showing that caffeine coun-
teracts other forms of toxicity. On the other hand, several
studies have shown that the role of adenosine can be
neuroprotective or neurotoxic depending on the type of
insult and the specific cellular conditions (Cunha 2001).
Therefore, it is reasonable to hypothesize that endogenous
adenosine may counteract MDMA-induced glial activa-
tion. Adenosine may in fact decrease blood pressure, heart
rate and induce hypothermia (Jonzon et al. 1986) as well
as regulate the actions of neurotrophic factors through
adenosine A2A receptors (Sebastia˜o and Ribeiro 2009). By
blocking both adenosine A1 and A2A receptors, caffeine
may facilitate neuroinflammatory processes induced by
MDMA. It should be, however, emphasized that our study
relates to acute caffeine treatment and that due to the
rapid tolerance developed to the drug, different results
might be obtained in a chronic protocol of caffeine
administration.
In conclusion, by activating astroglia and microglia
cells, the combination of MDMA plus caffeine enhanced
inflammatory brain processes induced by MDMA. Since
MDMA and energy drinks are very popular among young
438 Neurotox Res (2010) 17:435–439
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people, particular attention should be paid in the harmful
health consequences of this combination of drugs.
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Neuroprotective and Anti-inﬂammatory
Effects of the Adenosine A2A Receptor
Antagonist ST1535 in a MPTP Mouse Model
of Parkinson’s Disease
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ABSTRACT Adenosine A2A receptor antagonists are one of the most attractive
classes of drug for the treatment of Parkinson’s disease (PD) as they are effective in
counteracting motor dysfunctions and display neuroprotective and anti-inﬂammatory
effects in animal models of PD. In this study, we evaluated the neuroprotective and
anti-inﬂammatory properties of the adenosine A2A receptor antagonist ST1535 in a
subchronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD.
C57BL/6J mice were repeatedly administered with vehicle, MPTP (20 mg/kg), or
MPTP 1 ST1535 (2 mg/kg). Mice were sacriﬁced three days after the last administra-
tion of MPTP. Immunohistochemistry for tyrosine hydroxylase (TH) and cresyl violet
staining were employed to evaluate dopaminergic neuron degeneration in the substan-
tia nigra pars compacta (SNc) and caudate-putamen (CPu). CD11b and glial ﬁbrillary
acidic protein (GFAP) immunoreactivity were, respectively, evaluated as markers of
microglial and astroglial response in the SNc and CPu. Stereological analysis for TH
revealed a 32% loss of dopaminergic neurons in the SNc after repeated MPTP admin-
istration, which was completely prevented by ST1535 coadministration. Similarly, CPu
decrease in TH (25%) was prevented by ST1535. MPTP treatment induced an intense
gliosis in both the SNc and CPu. ST1535 totally prevented CD11b immunoreactivity
in both analyzed areas, but only partially blocked GFAP increase in the SNc and CPu.
A2A receptor antagonism is a new opportunity for improving symptomatic PD treat-
ment. With its neuroprotective effect on dopaminergic neuron toxicity induced by
MPTP and its antagonism on glial activation, ST1535 represents a new prospect for a
disease-modifying drug. Synapse 00:000–000, 2010. VC 2010 Wiley-Liss, Inc.
INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative
disorder characterized by motor dysfunctions because
of a progressive loss of dopaminergic neurons in the
substantia nigra pars compacta (SNc). Causes of this
neurodegeneration are not clear, but in the last dec-
ade evidence has linked it to intense neuroinﬂamma-
tion (Hirsch et al., 2003; McGeer and McGeer, 2008;
Rogers et al., 2007; Tansey et al., 2007; Teismann
et al., 2003; Whitton, 2007). In such inﬂammatory
states, activated glia can produce large quantities of
free radicals, cytokines, and other neurotoxic substan-
ces to which dopaminergic neurons appear very sensi-
tive and which could be related with the progression
of the disease (Hirsch et al., 1998; Hunot and Hirsch,
2003; McGeer et al., 2001).
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One of the main targets of research in PD is to
identify new molecules that are not only able to amel-
iorate motor symptoms but also protect dopaminergic
neurons and halt the progression of their degenera-
tion. Among the new therapies proposed, adenosine
A2A receptor antagonists are the best candidates,
since preclinical studies and clinical trials suggest
that these compounds may increase the therapeutic
efﬁcacy of L-3,4-dihydroxyphenylalanine (L-DOPA)
without exacerbating L-DOPA-associated dyskinetic
effects (Bara-Jimenez et al., 2003; Grondin et al.,
1999; Hauser et al., 2008; Kanda et al., 2000; Lewitt
et al., 2008; Morelli, 2003; Schwarzschild et al., 2006;
Stacy et al., 2008). Furthermore, epidemiological
studies have shown that the incidence of PD is lower
in consumers of high doses of caffeine, an antagonist
of adenosine A1 and A2A receptors (Ross et al., 2000).
A2A receptor antagonists have also been shown to
have a neuroprotective role in several experimental
rodent models of PD (Carta et al., 2009; Ikeda et al.,
2002; Pierri et al., 2005). In the case of 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated
mice, similar neuroprotection was obtained using A2A
receptor knockout mice (Carta et al., 2009). Interest-
ingly, A2A receptors are present in the basal ganglia,
particularly in the caudate-putamen (CPu), where
they are localized postsynaptically in GABAergic
striatopallidal neurons and presynaptically in cortical
nerve terminals (Ongini and Fredholm, 1996; Rebola
et al., 2005; Rosin et al., 1998; Schiffmann et al.,
2007; Svenningsson et al., 1999). Moreover, A2A recep-
tors are expressed in non-neuronal cell types, such as
microglia and astroglia (Fiebich et al., 1996; Saura
et al., 2005).
Previous studies have shown that the non-xanthine
compound 2-butyl-9-methyl-8-(2H-1,2,3-triazol-2-yl)-
9H-purin-6-ylamine (ST1535) has antiparkinson ac-
tivity since it blocks catalepsy induced by the adeno-
sine A2A receptor agonist CGS 21680 and by haloperi-
dol (Minetti et al., 2005; Stasi et al., 2006), and pro-
duces positive effects in acute models of parkinsonian
akinesia and tremor in rats (Pinna et al., 2007) and
monkeys (Rose et al., 2006). Moreover, when adminis-
tered subchronically in unilaterally 6-hydroxydopa-
mine (6-OHDA) lesioned rats with a threshold dose
of L-DOPA, ST1535 induced contralateral turning at a
similar intensity to that produced by a full dose of
L-DOPA without exacerbating its dyskinetic effects
(Tronci et al., 2007). In addition, ST1535 reduces
long-term neuronal modiﬁcations correlated to
L-DOPA motor side effects, as induction of the early
gene zif-268 mRNA (Tronci et al., 2007).
ST1535 also modulates corticostriatal glutamatergic
transmission (Tozzi et al., 2007), reduces striatal
extracellular glutamate levels (Galluzzo et al., 2008),
and protects the striatum against rotenone-induced
neurotoxicity (Belcastro et al., 2009).
Given the positive symptomatic preclinical studies,
the aim of the present study was to evaluate the neu-
roprotective and anti-inﬂammatory effects of ST1535
in a subchronic MPTP mouse model of PD. Neuron
damage and the neuroprotective effect of ST1535
were evaluated by tyrosine hydroxylase (TH) immu-
noreactivity and cresyl violet staining in the SNc,
whereas the antiinﬂammatory efﬁcacy of ST1535 was
evaluated in the SNc and CPu by immunohistochem-
istry for CD11b and glial ﬁbrillary acidic protein
(GFAP), as markers of microglia and astroglia, respec-
tively. Doses of ST1535 in this study were chosen on
the basis of previous studies performed with the pro-
totypical A2A receptor antagonist SCH58261, which
showed that ST1535 has a potency of about four
times lower than SCH58261 (Pinna et al., 2007,
2010).
MATERIALS AND METHODS
Drugs
The 2-butyl-9-methyl-8-(2H-1,2,3-triazol-2-yl)-9H-
purin-6-ylamine (ST1535) (Sigma-Tau, Italy) was dis-
solved in 5% dimethyl sulfoxide (DMSO), 45% polyeth-
ylene glycol 400 (PEG 400), and 50% water. MPTP-HCl
(Sigma, Italy and USA) was dissolved in water.
Treatments
Male C57BL/6J mice, 3 months old (Charles River,
Italy), were treated with vehicle (5% DMSO, 45%
PEG 400, and 50% water) (n 5 4–5 for TH analysis,
n 5 13–14 for CD11b and GFAP analysis); vehicle 1
MPTP (20 mg/kg, i.p.) (n 5 5 for TH analysis, n 5
13–16 for CD11b and GFAP analysis); or ST1535
(2 mg/kg, i.p.) 1 MPTP (20 mg/kg, i.p.) (n 5 5 for TH
analysis, n 5 13–16 for CD11b and GFAP analysis).
Mice received four doses of MPTP, administered once
a day for four days. During MPTP treatment, mice
received ST1535 or vehicle twice a day, 30 minutes
before and 12 hours after MPTP administration. Ani-
mals also received ST1535 or vehicle the day before
MPTP treatment once a day, and after MPTP treat-
ment discontinuation, once a day, until sacriﬁce,
which occurred three days after the last administra-
tion of MPTP. Mice were anesthetized with chloral
Abbreviations:
6-OHDA 6-hydroxydopamine
CPu caudate-putamen
DMSO dimethyl sulfoxide
GFAP glial ﬁbrillary acidic protein
L-DOPA L-3,4-dihydroxyphenylalanine
MPTP 1-methyl-4-phenyl-1,2,3,
6-tetrahydropyridine
PD Parkinson’s disease
PEG polyethylene glycol
ROI region of interest
SNc substantia nigra pars compacta
TH tyrosine hydroxylase
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hydrate (400 mg/kg, i.p.) and transcardially perfused
with paraformaldehyde (4% in 0.1 M phosphate
buffer, pH 7.4) for immunohistochemistry.
Immunohistochemistry and cresyl
violet staining
Sections from the SNc and CPu (50-lm thick) were
coronally cut on a vibratome and immunoreacted
with TH, CD11b, and GFAP antibodies (polyclonal
rabbit anti-TH, 1:1000, Biomol, UK; monoclonal rat
anti-mouse CD11b, 1:1000, Serotec, UK; monoclonal
mouse anti-GFAP, 1:400, Sigma, Italy), and proper
secondary antibodies (goat anti-rabbit immunoglobu-
lin G (IgG) for TH, goat anti-rat IgG for CD11b, and
goat anti-mouse IgG for GFAP, all from Vector, UK).
For visualization, the avidin/biotin-peroxidase proto-
col (ABC, Vector, UK) was applied, using 3,30-diami-
nobenzidine (Sigma, Italy) as chromogen. Sections
were mounted on gelatin-coated slides, dehydrated,
and cover slipped (Schintu et al., 2009a,b).
Adjacent SNc sections were stained with cresyl vio-
let to evaluate cell death in this area. Images were
digitized (PL-A686 video camera, Pixelink, Canada)
under constant light conditions. In each section, the
entire left and right SNc were analyzed, whereas for
the CPu evaluation, one portion from the dorsolateral
CPu and one from the ventromedial CPu (520 lm 3
380 lm), left and right, were analyzed. For each ani-
mal, three sections from the SNc (A 5 22.92 mm,
23.28 mm, 23.64 mm from bregma, according to the
mouse brain atlas by Paxinos and Franklin (2001))
and three sections from the CPu (A 5 1.10 mm, 0.74
mm, and 0.38 mm from bregma) were analyzed for
Fig. 1. Immunoreactivity for TH and cresyl violet staining in
SNc. Representative coronal sections of SNc immunostained for TH
and stained for cresyl violet (see inserts). Mice were treated with
MPTP (20 mg/kg once a day for four days, i.p.) plus vehicle or
ST1535 (2 mg/kg, i.p. twice a day during MPTP treatment, once a
day the day before and two days after MPTP) and sacriﬁced three
days after MPTP treatment. The graph shows the density of TH-
immunoreactive cells per mm3 expressed as a percentage with
respect to vehicle-treated mice. The graph on top right shows the
number of cresyl violet-positive cells expressed as a percentage with
respect to vehicle-treated mice. Values are expressed as mean 6
SEM. *P < 0.001 as compared to the vehicle-treated mice; ^P <
0.001 as compared to the MPTP-treated mice, by Tukey’s post hoc
test. n 5 4–5. Scale bar, 50 lm.
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each protein evaluated in the study and for cresyl-vio-
let-stained cells.
Stereological counting of TH-immunoreactive
neurons
TH-immunoreactive neurons were counted on both
hemispheres. All stereological counting was performed
using a Leica microscope (DMLB; Leica, Denmark)
equipped with a camera (Basler Vision Technologies,
Germany) and a stage connected to an xyz stepper
(PRIOR ProScan) and the newCAST Visiopharm (Den-
mark) software. The SNc region was outlined at low
magniﬁcation (53) for area estimation. The number of
labeled neurons was calculated under 633magniﬁcation
using randomized meander sampling and optical dissec-
tor methods. The cut thickness of sections was 50 lm
and the optical dissector height was 12 lm. The top (13
lm) and bottom (25 lm) layers that shrunk during stain-
ing procedure were discarded. The sampling area cov-
ered 100% of the region of interest (ROI). The counting
frame (8302,8 lm2) applied the exclusion and inclusion
lines, and unbiased counting was performed by an exper-
imenter blinded to the treatment. Results are presented,
according to Carta et al. (2009), as the mean of TH-im-
munoreactive neurons per mm3 6SEM, calculated using
the following formula:
D ¼ RQ=V sampling
where D 5 density of labeled cells per mm3, V sam-
pling 5 area of the region of interest 3 dissector
height, Q 5 total count of labeled neurons.
In addition, we have extrapolated the numbers of
dopaminergic neurons in whole SNc using the follow-
ing formula:
N ¼ D 3 V
where D 5 density of cells per mm3, V 5 volume of
the SNc.
The volume of SNc was reconstructed by calculat-
ing the distance among the three slices, multiplied by
the outlined area.
Analysis of TH immunoreactivity in the CPu
Images were digitized in gray scale, and TH immuno-
reactivity analysis in the CPu was performed using the
image analysis program Scion Image (Scion Corp.,
USA). The average gray values from white matter were
subtracted from each section to correct for background
immunoreactivity. For each level of CPu, the obtained
value was ﬁrst normalized with respect to vehicle, and
values from different levels were averaged thereafter.
Analysis of GFAP immunoreactivity
For each SNc and CPu level, the mean number of
GFAP-positive cells obtained from each experimental
group was ﬁrst normalized with respect to vehicle, and
values from different levels were averaged thereafter.
Analysis of CD11b immunoreactivity
Images were digitized in grayscale and CD11b immu-
nostaining was evaluated with the analysis program
Scion Image (Scion Corp., USA). A threshold, whose
value was set above the mean value 6SEM of the back-
ground, was applied for background correction. Inside
each frame, the area occupied by gray values above the
threshold was automatically calculated. For each level
of SNc or CPu, the obtained value was ﬁrst normalized
with respect to vehicle, and values from different levels
were averaged thereafter.
Statistics
All data were statistically analyzed with a 1-way
ANOVA, followed by Tukey’s post hoc test. Results
were considered signiﬁcant at P < 0.05.
RESULTS
ST1535 prevented neurodegeneration induced
by MPTP in the SNc and CPu
MPTP treatment (20 mg/kg 3 4, i.p.) induced a sig-
niﬁcant loss of TH-positive neurons in the SNc (32%),
as measured by stereological counting (Fig. 1). Treat-
ment with ST1535 (2 mg/kg, i.p.) 1 MPTP completely
prevented any loss of TH-positive cells (n 5 4–5;
F(2,11) 5 17.82; P < 0.001).
In addition, total number of cells in the SNc was
extrapolated as described in Material and Methods
(vehicle: 20,498 6 1437; MPTP: 13,344 6 582; MPTP
1 ST1535: 17,375 6 612; n 5 4–5; F(2,11) 5 16.34; P
< 0.001).
To determine the effective neurodegeneration, adja-
cent SNc sections were stained with cresyl violet.
Fig. 2. Immunoreactivity for TH in CPu. Mice were treated
with MPTP (20 mg/kg once a day for four days, i.p.) plus vehicle or
ST1535 (2 mg/kg, i.p. twice a day during MPTP treatment, once a
day the day before and two days after MPTP) and sacriﬁced three
days after MPTP treatment. The graph shows the mean density of
gray value of TH expressed as a percentage with respect to vehicle-
treated mice. Values are expressed as mean 6 SEM. *P < 0.001 as
compared to the vehicle-treated mice; ^P < 0.001 as compared to
the MPTP-treated mice, by Tukey’s post hoc test. n 5 5–6.
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Stained cells in the SNc conﬁrmed neuron loss with
MPTP and the complete prevention of neuron loss with
ST1535 (Fig. 1) (n 5 4–5; F(2,11) 5 43.58; P < 0.001).
MPTP treatment (20 mg/kg 3 4, i.p.) induced a
similar signiﬁcant decrease of TH in the CPu (25%),
(Fig. 2). Treatment with ST1535 1 MPTP completely
prevented any loss of TH in the CPu (n 5 5–6; F(2,13)
5 38.00; P < 0.001).
ST1535 counteracted glial activation induced by
MPTP in the SNc and CPu
In vehicle-treated mice, resting microglia and very
low levels of CD11b were detected, both in the SNc
and CPu. Subchronic MPTP treatment induced a sig-
niﬁcant increase in CD11b immunoreactivity, and
microglia showed an ameboid aspect, in both the SNc
and CPu (Fig. 3). Combined treatment with ST1535
(2 mg/kg, i.p.) 1 MPTP (20 mg/kg 3 4, i.p.) com-
pletely prevented the increase in CD11b immuno-
staining in both the SNc and CPu (Fig. 3) (n 5 13;
F(2,36) 5 8.84; P < 0.001 in the SNc and n 5 13–16;
F(2,41) 5 10.63; P < 0.001 in the CPu).
Few astroglial cells were observed in vehicle-
treated mice. Moreover, GFAP-positive cells displayed
a highly branched morphology with tiny processes
and a small body. MPTP treatment (20 mg/kg 3 4,
Fig. 3. Immunoreactivity for CD11b in SNc and CPu. Represen-
tative sections of SNc (A) and CPu (B) immunostained for CD11b.
Mice were treated with MPTP (20 mg/kg once a day for four days,
i.p.) plus vehicle or ST1535 (2 mg/kg twice a day during MPTP treat-
ment, once a day the day before and two days after MPTP) and sacri-
ﬁced three days after MPTP treatment. The area occupied by gray
values above a threshold was calculated and expressed as square pix-
els and as a percentage of staining in vehicle-treated mice in the SNc
(A) and CPu (B). Values are expressed as mean 6 SEM. *P < 0.001
as compared wih the vehicle-treated mice; ^P < 0.001 as compared
with the MPTP-treated mice, by Tukey’s post hoc test. n 5 13 in the
SNc and n 5 13–16 in the CPu. Scale bar, 50 lm.
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i.p.) was associated with a higher number of GFAP-
positive cells and cells became hypertrophic (Fig. 4).
ST1535 (2 mg/kg, i.p.) signiﬁcantly but only partially
counteracted the MPTP-induced astrogliosis, both in
the SNc and CPu (Fig. 4) (n 5 14–15; F(2,40) 5 57.94;
P < 0.001 in the SNc and n 5 14–15; F(2,41) 5 712.47;
P < 0.001 in the CPu).
DISCUSSION
Results obtained in the present study show how the
A2A receptor antagonist ST1535 prevented MPTP-
induced TH-positive cell loss in the SNc. Cresyl violet
staining conﬁrmed cell death after MPTP treatment,
whereas the combination of MPTP 1 ST1535 offered
complete protection against neurodegeneration. These
results are in line with previous evidence that A2A re-
ceptor antagonist administration is neuroprotective
against the degeneration of dopaminergic neurons
induced by MPTP or 6-OHDA in animal models of PD
(Chen et al., 2001; Ikeda et al., 2002; Pierri et al.,
2005; Wardas, 2002). It should be emphasized that in
the present study, as in the majority of neuroprotec-
tive studies, the A2A antagonist was given before
MPTP administration. Therefore, extrapolation of
results to clinical application should take into account
Fig. 4. Immunoreactivity for GFAP in SNc and CPu. Represen-
tative sections of SNc (A) and CPu (B) immunostained for GFAP.
Mice were treated with MPTP (20 mg/kg once a day for four days,
i.p.) plus vehicle or ST1535 (2 mg/kg twice a day during MPTP
treatment, once a day the day before and two days after MPTP) and
sacriﬁced three days after MPTP treatment. Graphs show the num-
ber of GFAP-positive cells expressed as a percentage with respect to
vehicle-treated mice in the SNc (A) and CPu (B). Values are
expressed as mean 6 SEM. *P < 0.001 as compared to the vehicle-
treated mice; ^P < 0.001 as compared to the MPTP-treated mice, by
Tukey’s post hoc test. n 5 14–15. Scale bar, 50 lm.
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that when diagnosis of PD is made dopaminergic neu-
ron degeneration is already up to 70–80%, and there-
fore a neuroprotective strategy in the clinic should
stop rather than preventing neurodegeneration. This
consideration, however, does not affect the relevance
of the neuroprotective action of ST1535, considering
the different progression of dopaminergic neuron
degeneration: rapid in rodent models, very slow
(about 5–10 years) in humans.
The mechanism by which A2A receptor blockade
mediates neuroprotection in PD remains unclear. A2A
receptor stimulation increases glutamate release in
the CPu through modulation of neuronal terminals
and, possibly, indirectly in subthalamic neurons pro-
jecting to the SNc, which are controlled by GABA
release from the globus pallidus (Marchi et al., 2002;
Marcoli et al., 2003; Melani et al., 2003; Popoli et al.,
1995; Schwarzschild et al., 2003). Therefore, a possi-
ble glutamate-related mechanism could be envisioned
whereby A2A receptor blockade may protect dopami-
nergic neurons in models of PD by antagonizing the
increase in glutamate to toxic levels.
Besides an active role of glutamate in neurodegen-
eration, several ﬁndings have suggested that neuroin-
ﬂammation may play a role in the pathogenesis of
neurodegeneration in PD, since reactive astrogliosis
and microgliosis have been described in the SNc of
PD patients and MPTP-treated primates (Barcia
et al., 2004; Hunot and Hirsch, 2003). In addition,
activation of microglia has been shown to be a pri-
mary factor in the neurodegenerative process of PD
(Meredith et al., 2005), and blockade of microglial
reactivity in mice protects dopaminergic neurons from
acute MPTP toxicity (Teismann and Ferger, 2001; Wu
et al., 2002).
Recent data have shown that A2A receptor antago-
nism counteracts neuroinﬂammatory processes (Carta
et al., 2009; Huang et al., 2006) by inhibiting astro-
glial and microglial activation (Ikeda et al., 2002;
Pierri et al., 2005). In accordance with this, A2A re-
ceptor knockout mice displayed reduced astrogliosis
and microgliosis after subchronic MPTP administra-
tion (Carta et al., 2009).
The results obtained in the present study show
complete inhibition of microglial reactivity after
ST1535 treatment, in line with previous evidence
obtained with other A2A receptor antagonists on neu-
roinﬂammation induced by MPTP administration in
mice (Carta et al., 2009; Ikeda et al., 2002; Pierri
et al., 2005).
MPTP treatment also induced intense astrogliosis
in both the SNc and CPu, a phenomenon character-
ized by increased proliferation, hypertrophy, and elon-
gation of cellular GFAP-positive processes (Neary
et al., 1996; Ridet et al., 1997). Increased GFAP im-
munoreactivity has also been detected in the SNc of
monkeys 1 year after chronic MPTP intoxication and
in postmortem CPu from parkinsonian patients
(Barcia et al., 2004; Langston et al., 1999; McGeer
et al., 1988). ST1535 displays positive effects in coun-
teracting astrogliosis; however, in contrast with
microglia, reactive astroglia were only partially inhib-
ited by ST1535 both in the SNc and CPu. The partial
antagonism of astroglia activation is not surprising
since astroglia is, in general, less sensitive than
microglia to A2A receptor antagonism-mediated anti-
inﬂammatory effects and is in line with previous ﬁnd-
ing obtained in A2A receptor knockout mice (Carta
et al., 2009).
The counteraction of dopaminergic neuron degener-
ation and glial activation shown by ST1535 in the
present study and the improvements observed in
motor deﬁcits when the drug is used in addition to
low doses of L-DOPA (Tronci et al., 2007) make this a
very interesting alternative drug for adjunctive ther-
apy in PD.
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